


## The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids

### Graphical Abstract



### Authors

Ayesh K. Seneviratne, Mingjing Xu,  
 Juan J. Aristizabal Henao, ...,  
 Ken D. Stark, Paul LeBlanc,  
 Aaron D. Schimmer

### Correspondence

aaron.schimmer@uhn.ca

### In Brief

Seneviratne et al. performed a CRISPR screen and identified tafazzin (TAZ) as important for the growth of leukemia cells. The inhibition of TAZ specifically reduced the stemness of leukemia cells by increasing phosphatidylserine levels and activating toll-like receptor signaling.

### Highlights

- Inhibiting TAZ leads to increased levels of PS in AML cells
- TAZ and PS regulate AML stemness
- Reducing TAZ or increasing PS decreases AML stemness and activates TLR signaling
- Increasing PS is a potential therapeutic strategy for AML

# The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids

Ayesh K. Seneviratne,<sup>1,2,15</sup> Mingjing Xu,<sup>1,15</sup> Juan J. Aristizabal Henao,<sup>3</sup> Val A. Fajardo,<sup>4</sup> Zhenyue Hao,<sup>1</sup> Veronique Voisin,<sup>5</sup> G. Wei Xu,<sup>1</sup> Rose Hurren,<sup>1</sup> S. Kim,<sup>1</sup> Neil MacLean,<sup>1</sup> Xiaoming Wang,<sup>1</sup> Marcela Gronda,<sup>1</sup> Danny Jeyaraju,<sup>1</sup> Yulia Jitkova,<sup>1</sup> Troy Ketela,<sup>1</sup> Michael Mullokandov,<sup>6</sup> David Sharon,<sup>1</sup> Geethu Thomas,<sup>1</sup> Raphaël Chouinard-Watkins,<sup>7</sup> James R. Hawley,<sup>1,14</sup> Caitlin Schafer,<sup>8</sup> Helen Loo Yau,<sup>1,14</sup> Zaza Khuchua,<sup>9,10</sup> Ahmed Aman,<sup>11,12</sup> Rima Al-awar,<sup>11,12</sup> Atan Gross,<sup>6</sup> Steven M. Claypool,<sup>13</sup> Richard Bazinet,<sup>7</sup> Mathieu Lupien,<sup>1,14</sup> Steven Chan,<sup>1,14</sup> Daniel D. De Carvalho,<sup>1,14</sup> Mark D. Minden,<sup>1,14</sup> Gary D. Bader,<sup>5</sup> Ken D. Stark,<sup>3</sup> Paul LeBlanc,<sup>4</sup> and Aaron D. Schimmer<sup>1,2,14,16,\*</sup>

<sup>1</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

<sup>2</sup>Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

<sup>3</sup>Laboratory of Nutritional Lipidomics, Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada

<sup>4</sup>Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada

<sup>5</sup>Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

<sup>6</sup>Department of Biological Regulation, Weizmann Institute, Rehovot, Israel

<sup>7</sup>Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

<sup>8</sup>Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

<sup>9</sup>Department of Biochemistry, Sechenov Medical University, Moscow, Russian Federation

<sup>10</sup>Institute of Medical Research Ilia State University, Tbilisi, Georgia

<sup>11</sup>Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada

<sup>12</sup>Department of Pharmacology and Toxicology, University of Toronto, ON, Canada

<sup>13</sup>Department of Physiology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA

<sup>14</sup>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

<sup>15</sup>These authors contributed equally

<sup>16</sup>Lead Contact

\*Correspondence: [aaron.schimmer@uhn.ca](mailto:aaron.schimmer@uhn.ca)

<https://doi.org/10.1016/j.stem.2019.02.020>

## SUMMARY

Tafazzin (TAZ) is a mitochondrial transacylase that remodels the mitochondrial cardiolipin into its mature form. Through a CRISPR screen, we identified TAZ as necessary for the growth and viability of acute myeloid leukemia (AML) cells. Genetic inhibition of TAZ reduced stemness and increased differentiation of AML cells both *in vitro* and *in vivo*. In contrast, knockdown of TAZ did not impair normal hematopoiesis under basal conditions. Mechanistically, inhibition of TAZ decreased levels of cardiolipin but also altered global levels of intracellular phospholipids, including phosphatidylserine, which controlled AML stemness and differentiation by modulating toll-like receptor (TLR) signaling.


## INTRODUCTION

Hematopoiesis is a hierarchical process in which hematopoietic stem cells give rise to differentiated precursors and mature blood cells. Like hematopoiesis, acute myeloid leukemia (AML) is also hierarchical with leukemic stem and progenitor

cells giving rise to mature and differentiated leukemic blasts (Corces-Zimmerman et al., 2014; Jan et al., 2012; McCracken et al., 2016).

AML cells and stem cells have unique mitochondrial and metabolic features with greater reliance on oxidative phosphorylation (Cole et al., 2015; Kuntz et al., 2017; Lagadinou et al., 2013; Skrtić et al., 2011). Inhibiting mitochondrial processes such as mitochondrial protein translation impairs oxidative phosphorylation and is selectively cytotoxic to AML cells and stem cells (Skrtić et al., 2011). Thus, we conducted a genome-wide CRISPR screen for mitochondrial pathways whose inhibition targets AML cells and identified TAZ (Figure 1A).

Tafazzin (TAZ) is an X-linked gene that encodes a mitochondrial transacylase that is required for the production of the mitochondrial phospholipid cardiolipin (Lu and Claypool, 2015; Lu et al., 2016; Paradies et al., 2014). Cardiolipin is synthesized by a cascade of enzymes located in the cytoplasm and inner mitochondrial membrane (Figure 1C). Once synthesized, nascent cardiolipin is remodeled into a mature cardiolipin molecule (Claypool and Koehler, 2012; Lu and Claypool, 2015; Malhotra et al., 2009). TAZ is the enzyme responsible for the majority of cardiolipin remodeling under physiological conditions. Mutations or loss of TAZ leads to reductions in mature cardiolipin and increases the remodeling intermediate monolysocardiolipin (MLCL) (Claypool and Koehler, 2012; Lu and Claypool, 2015; Malhotra et al., 2009). Our objective was to characterize the role of TAZ in AML and hematopoiesis.



**Figure 1. CRISPR Screens Identify TAZ as an Essential Gene for the Growth and Viability of AML Cells**

(A) Results of a dropout screen in Cas9-OCI-AML2 cells. Positive-hits were identified at a false discovery rate (FDR) <5%.

(B) The rank of TAZ in screens of OCI-AML2, OCI-AML3, MOLM-13, MV4-11, and HL-60 cells from the published CRISPR dropout screens by Tzelepis et al. (2016).

(legend continued on next page)

## RESULTS

### A CRISPR Screen Identifies TAZ as Essential for Growth and Viability of AML Cells

CAS9-expressing human OCI-AML2 leukemia cells were transduced with a library of 91,320 small guide RNAs (sgRNAs) in bar-coded lentiviral vectors targeting 17,232 nuclear-encoded genes. Cells were harvested, genomic DNA was isolated, and the relative abundance of sgRNAs was determined by sequencing barcodes 17 days after transduction. sgRNAs able to reduce the viability or growth of OCI-AML2 cells were inferred to be those not represented in the final cell population. In analyzing the data, we focused on the sgRNAs targeting the 1,049 nuclear-encoded mitochondrial proteins. Top hits included sgRNAs targeting dihydroorotate dehydrogenase (*DHODH*), B cell lymphoma 2 (*BCL2*), and components of the mitochondrial ribosome, all of which have been previously shown to be necessary for the growth and viability of AML cells and stem cells (Table S1) (Skrtić et al., 2011; Sykes et al., 2016). We also identified the cardiolipin remodeling enzyme *TAZ* among the top 1% of mitochondrial hits (Figure 1A; Table S1). Of note, *TAZ* was also in the top 0.5% of hits in the whole genome. We also analyzed data from previously published CRISPR screens (Tzelepis et al., 2016) and identified *TAZ* as essential for the growth and viability of the leukemic cell lines OCI-AML2, OCI-AML3, MOLM-13, MV4-11, and HL-60 (Figure 1B).

*TAZ* is involved in the production of the mitochondrial-specific phospholipid cardiolipin (Claypool and Koehler, 2012; Lu and Claypool, 2015; Lu et al., 2016; Paradies et al., 2014) (Figure 1C) and we focused our investigation on this target. Using individual sgRNA, we confirmed that knockout of *TAZ* reduced the growth of CAS9-OCI-AML2 cells, thus validating the findings from our screen (Figure 1D).

### Genetic Deficiency of TAZ Decreases Stemness and Increases Differentiation in AML

To understand how *TAZ* affects the growth of leukemia, OCI-AML2, TEX, U-937, and K562 leukemia cells were transduced with two independent short hairpin RNA (shRNA) targeting *TAZ* or control sequences in lentiviral vectors. Similar to knockout of *TAZ* by CRISPR, *TAZ* knockdown inhibited the growth of the tested leukemia cells (Figures 1E, 1F, S1A, and S1B). *TAZ* knockdown induced cell-cycle arrest but not apoptosis as measured by Annexin V staining (Figures S1C–S1F).

Leukemia stem and progenitor cells initiate and drive the propagation of AML, so we assessed the effects of *TAZ* knockdown on AML stem and progenitors and differentiation. First, we analyzed global changes in gene expression by RNA sequencing after *TAZ* knockdown in OCI-AML2 cells. The gene expression

profile of *TAZ* knockdown AML cells was compared with genes that characterize primary AML stem cells ( $LSC^+$ ) and bulk cells ( $LSC^-$ ) (Ng et al., 2016). *TAZ* knockdown increased expression of genes associated with  $LSC^-$  cells and decreased expression of genes associated with  $LSC^+$  cells (Figures 2A and 2B). As shown in Shlush et al. (2017), unsupervised clustering can be used to divide the TCGA AML cohort into two distinct clusters: one TCGA cluster is similar to stem- and progenitor-like cells, and the other TCGA cluster is similar to more mature myeloid cells (Figure S2A). Per the *LSC* gene set enrichment analysis, *TAZ* knockdown increased the expression of genes associated with the TCGA myeloid-like cluster and decreased the expression of genes in the TCGA stem- and progenitor-like cluster (Figure S2B). Besides, the gene expression after *TAZ* knockdown was compared to 20 different sub-fractions of normal hematopoietic cells from 38 human samples (Novershtern et al., 2011). Genes associated with more differentiated myeloid populations such as granulocyte-neutrophils were increased, after *TAZ* knockdown (Figures S2C and S2D).

Given the changes in gene expression, we characterized the cellular phenotype of OCI-AML2 cells after *TAZ* knockdown. Non-specific esterase (Figure 2C), a marker of monocytic differentiation *in vitro*, was increased, although no changes in macrophage markers CD11b and CD14 were seen (Figures S2E and S2F). Increased differentiation was also observed when *TAZ* knockdown cells were grown *in vivo*, with increased expression of the myeloid granule protein, lysozyme (Sykes et al., 2016) (Figure S2G).

We then evaluated the effects of *TAZ* knockdown on stem and progenitor cell functions both *in vitro* and *in vivo*. In methylcellulose assays, *TAZ* knockdown reduced the clonogenic growth of OCI-AML2 and TEX cells. The reduction in clonogenic growth persisted upon serial re-plating (Figures 2D, 2E, and S2H). In xenotransplantation assays, *TAZ* knockdown in TEX cells reduced bone marrow engraftment in NOD-SCID-GF mice, suggesting that *TAZ* knockdown reduces AML propagation by reducing AML stemness both *in vitro* and *in vivo* (Figure 2F).

### TAZ Knockdown Mice Have Normal Hematopoiesis

To assess the effects of *TAZ* inhibition on normal hematopoiesis *in vivo*, we analyzed doxycycline-inducible *TAZ* knockdown (iDOX-*Taz*-KD) mice. (Acehan et al., 2011; Soustek et al., 2011). 7.6- to 14.3-week-old adult iDOX-*Taz*-KD were fed DOX to induce *Taz* knockdown. After 12–19.4 weeks of DOX induction, we measured levels of *TAZ* and phospholipid levels. We observed reduced *TAZ* protein levels and an expected increase of the MLCL:cardiolipin ratio in bone marrow mononuclear cells (Figure 3A).








We then analyzed the hematopoietic system in these mice. *Taz* knockdown mice had normal levels of hemoglobin, white blood

(C) A model of the enzymatic steps involved in cardiolipin synthesis and remodeling, where *TAZ* utilizes phosphatidylcholine (PC) or phosphatidylethanolamine (PE) as acyl chain donors to reacylate monolysocardiolipin (MLCL).

(D) Proliferation of CAS-9-OCI-AML2 cells after CRISPR-mediated knockout of *TAZ*. The relative area under the curve (AUC) of viable cell counts over 12 days are shown. Control sgRNA = 100%. Data are mean  $\pm$  SEM ( $N = 3$ ). \*\*\*\* $p \leq 0.0001$  by one-way ANOVA and Dunnett's post hoc test.

(E and F) Proliferation and *TAZ* protein expression of OCI-AML2 (E) and TEX cells (F) after shRNA-mediated *TAZ* knockdown. The relative AUC of viable cell counts over 12 days are shown (control shRNA = 100%). Data are mean  $\pm$  SD ( $n = 2$ ) of a representative experiment from 3 independent experiments. \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$  by one-way ANOVA and Dunnett's post hoc test.

See also Figure S1 and Table S1.



(legend on next page)

cells, neutrophils, and platelets (Figure 3B). We also enumerated the frequency of hematopoietic stem and progenitor cells by flow cytometry. *Taz* knockdown mice had normal levels of long-term hematopoietic stem cells (LT-HSC), short-term hematopoietic stem cells (ST-HSC), multipotent progenitor cells (MPP), megakaryocyte-erythroid progenitor cells (MEP), common myeloid progenitor cells (CMP), and granulocyte/monocyte progenitor cells (GMP) (Figure 3C; Table S2).

To determine the role of TAZ in hematopoietic stress, wild-type (WT) or *Taz* knockdown mice were treated with 200 mg/kg of 5-fluorouracil (5-FU), and changes in white blood cells, neutrophils, lymphocytes, erythrocytes, and platelets were monitored (Figures S3A–S3F). WT and *Taz*-KD mice demonstrated reversible cytopenias after 5-FU treatment. Compared to controls, *Taz* knockdown mice showed decreased numbers of ST-HSC and increased numbers of GMP after 5-FU treatment (Figure 3D; Table S2). However, we observed little or no change in clonogenic growth in primary and serial re-plating experiments (Figure S3G). Thus, the lack of effect on stem cell function contrasts with the effects on AML cells.

### TAZ Knockdown Alters Levels of Cellular Phospholipids

To understand the effects of TAZ knockdown on cardiolipin levels and composition in leukemia, we knocked down TAZ in OCI-AML2 cells and measured levels of MLCL and cardiolipin. As expected, TAZ knockdown increased MLCL:cardiolipin ratio (Figure 4A) in AML cells. TAZ also determined the final acyl composition of cardiolipin (Lu and Claypool, 2015; Lu et al., 2016; Paradies et al., 2014). Interestingly, TAZ knockdown AML cells had more cardiolipin acyl species with >5 double bonds (Figure 4B), as well as longer MLCL and cardiolipin acyl chain lengths (Figures S4A and S4B). Also, the predominant cardiolipin species in AML switched from 68:4 to 70:5 (Figures S4C–S4H). Cardiolipin binds to and activates caspase-8, which cleaves pro-apoptotic BID into t-bid, and facilitates extrinsic apoptosis (Gonzalez et al., 2008; 2013). Mutation or deletion of TAZ renders cells resistant to extrinsic apoptosis. Similarly, TAZ knockdown rendered OCI-AML2 cells resistant to extrinsic apoptosis (Figure S4I). Thus, taken together, TAZ knockdown produced functionally significant reductions in levels of the phospholipid cardiolipin.

Cardiolipin is required for the stability, proper localization, and efficient function of respiratory chain enzymes (Paradies et al., 2014). However, we observed no decrease in basal oxygen consumption (Figure S4J), electron transport chain reserve capacity (Figure S4K), cellular ROS production (Figure S4L), mitochondrial mass (Figure S4M), mitochondrial structure by electron

microscopy (Figure S4N), or mitochondrial length by confocal microscopy (Figure S4O). Thus, the change in cardiolipin levels after TAZ knockdown was not sufficient to impact mitochondrial structure or oxidative phosphorylation. It is noteworthy that, we did observe a decrease in glycolysis, which is consistent with differentiation (Figure S4P) (Gu et al., 2016).

Phospholipids are organized in a highly interconnected network, and perturbations in one species affect levels of other phospholipids (Köberlin et al., 2015). Therefore, we measured changes in cellular phospholipids by high-performance thin-layer chromatography (HPLC) after TAZ knockdown in OCI-AML2 and observed decreased levels of cardiolipin, as well as phosphatidylethanolamine (PE), increased levels of phosphatidylserine (PS), but no change in phosphatidylcholine (PC), phosphatidylinositol (PI), and sphingomyelin (SM) (Figure 4C). Of note, the increase in PS was intracellular, and no increase in PS was detected on the cell surface (Figure 4D).

We also evaluated changes in PS after TAZ knockdown in primary AML cells and the primary AML culture system 8227 (Lechman et al., 2016). TAZ knockdown increased intracellular PS in primary AML and 8227 cells (Figures S5A–S5C).

### Increasing Intracellular PS Decreases AML Stemness and Increases Differentiation in AML

We then determined whether the changes in PE and PS were functionally essential to explain the effects of TAZ knockdown on AML. First, we tested whether the supplementation of PE or the PE substrate lysophosphatidylethanolamine (LPE) could protect cells from TAZ knockdown. Despite increasing PE levels, we saw no protection from TAZ knockdown by supplementing AML cells with PE or LPE (Figures S5D and S5F). Next, we tested whether supplementing cells with PS could increase differentiation and decrease stemness in AML. Supplementing AML cells with PS increased intracellular levels of PS and the PS:PE ratio (Figure 4E) and decreased AML cell growth (Figure 4F). Furthermore, pre-treatment of leukemia cells with PS reduced AML clonogenic growth (Figures 4G and 4H) and engraftment into mice (Figures 4I–K). PS decarboxylase (PISD) converts PS to PE in the inner mitochondrial membrane (Figure 4L), and we discovered that recombinant PISD binds preferentially to cardiolipin and the cardiolipin moiety phosphatidylglycerol (Figure 4M). Knockdown of TAZ decreased levels of PISD protein but not mRNA (Figure S5G) and did not change the levels of the PS synthesis enzymes PSS1 and PSS2 (Figure S5H). Therefore, to further characterize the effects of increasing PS on AML stemness and differentiation we evaluated the effects of PISD inhibition in AML. First, we knocked out PISD in CAS9-OCI-AML2 cells

### Figure 2. TAZ Knockdown Reduces AML Stemness

(A) Heatmap of standardized Z score expression of the 500 most highly upregulated genes in OCI-AML2 cells after TAZ shRNA knockdown. Rows represent genes and columns represent LSC<sup>+</sup> (pink bars) or LSC<sup>-</sup> (black bars) fractions.


(B) Gene set enrichment analysis (GSEA) of OCI-AML2 cells from (A). The normalized enrichment scores (NES), and false discovery rates (FDRs) are indicated in each GSEA plot.

(C) Non-specific esterase (NSE) staining of OCI-AML2 cells after TAZ shRNA knockdown. Data are relative mean  $\pm$  SEM (N = 4, control shRNA = 1.0 ABU). \*\*\*\*p  $\leq$  0.0001 by one-way ANOVA and Dunnett's post hoc test.

(D and E) Clonogenic growth of OCI-AML2 (D) or TEX (E) after TAZ shRNA knockdown. Data are relative mean  $\pm$  SEM (N = 3, control shRNA = 100%). \*\*\*\*p  $\leq$  0.0001 by one-way ANOVA and Dunnett's post hoc test.

(F) CD45<sup>+</sup> TEX cell engraftment after TAZ shRNA knockdown. Bar represents mean (n = 10 mice control shRNA group, n = 9 mice TAZ shRNA2 group). \*\*p  $\leq$  0.01 by Student's t test.

See also Figure S2.



**Figure 3. TAZ Knockdown Mice Are Viable with Normal Hematopoiesis but Have Reduced Numbers of Hematopoietic Stem Cells after Stress**


(A) TAZ expression and the MLCL:Cardiolipin ratio of 7.6- to 14.3-week-old wild-type (WT) and iDox-Taz-shRNA transgenic mice treated with doxycycline for 12.9–19.4 weeks to induce TAZ knockdown. Data are mean  $\pm$  SEM (N = 3 mouse groups, n = 7 WT mice, and n = 6 Taz-KD mice). \*\*\*\*p  $\leq$  0.0001 by Student's t test.

(B) Hemoglobin, white blood cells, neutrophils, and platelets of WT and Taz-KD mice treated with doxycycline as in (A). Data are mean  $\pm$  SEM (N = 6 mouse groups, n = 13 WT mice, and n = 14 Taz-KD mice).

(C) The frequency of Lin<sup>-</sup>cKit<sup>+</sup>Sca1<sup>+</sup> (LSK), Lin<sup>-</sup>cKit<sup>+</sup> (LK), multipotent progenitor cells (MPP, CD48<sup>+</sup>,CD150<sup>-</sup>), short-term hematopoietic stem cells (ST-HSC, CD48<sup>+</sup>,CD150<sup>+</sup>), long-term hematopoietic stem cells (LT-HSC, CD48<sup>+</sup>,CD150<sup>+</sup>), common myeloid progenitor cells (CMP, CD34<sup>+</sup>, Fc $\gamma$ R<sup>-</sup>), granulocyte-macrophage progenitor cells (GMP, CD34<sup>+</sup>, Fc $\gamma$ R<sup>+</sup>), megakaryocyte-erythrocyte progenitors (MEP, CD34<sup>+</sup>, Fc $\gamma$ R<sup>-</sup>) of WT and Taz-KD mice treated with doxycycline as in (A). Data are mean  $\pm$  SEM (N = 4 mouse groups, n = 10 WT mice, and n = 8 Taz-KD mice).

(D) The frequency of LSK, LK, MPP, ST-HSC, LT-HSC, CMP, GMP, MEP in WT and Taz-KD 15 days after being injected with 5-FU. Both WT and Taz-KD mice were treated with doxycycline as in (A). Data are mean  $\pm$  SEM (N = 2 mouse groups, n = 5 WT mice, and n = 6 Taz-KD mice). \*p  $\leq$  0.05, \*\*p  $\leq$  0.01 by two-way ANOVA and Bonferroni post hoc test.

See also Figure S3.



(legend on next page)

using sgRNA sequences in lentiviral vectors. Knockout of PISD was confirmed by immunoblotting (Figure 4N). The knockout of PISD increased the PS:PE ratio (Figure 4O) and reduced the growth (Figure 4P) and clonogenic growth (Figures 4Q and S5I) of CAS9-OCI-AML2 cells, without decreasing basal oxygen consumption or electron-transport chain reserve capacity in OCI-AML2 cells (Figures S5J and S5K). Furthermore, the overexpression of PISD rescued the differentiation phenotype of TAZ knockdown AML cells (Figures S5L and S5M).

As a chemical approach to inhibit PISD and increase intracellular levels of PS, we tested the reported inhibitor of Plasmodium falciparum PISD, MMV007285 (Figure 5A) (Choi et al., 2016; Lucantoni et al., 2013). Consistent with its effects as a PISD inhibitor, MMV007285 increased the PS:PE ratio in OCI-AML2 cells (Figure 5B). Concentrations of MMV007285 that increased PS also decreased growth (Figure 5C) and increased differentiation as evidenced by increase in non-specific esterase staining and CD11b expression (Figures 5D and 5E).

To understand the effects of inhibiting PISD and increasing PS on stemness in primary AML cells, we tested MMV007285 in the 8227 primary AML culture system. 8227 cells are arranged in a hierarchy of bulk and stem cells with the stem cells enriched in the CD34<sup>+</sup>38<sup>-</sup> fraction. Treatment with MMV007285 decreased the abundance of the CD34<sup>+</sup>38<sup>-</sup> stem cells (Figure 5F).

We also examined the effects of MMV007285 on the clonogenic growth of primary AML (N = 3) and normal hematopoietic cell (N = 3) samples. MMV007285 increased PS and inhibited the clonogenic growth of primary AML cells (Figures 5G and 5H) but did not affect the clonogenic growth of normal hematopoietic cells (Figure 5I). MMV007285 also did not alter the clonogenic growth of normal murine hematopoietic cells under conditions of hematopoietic stress (Figure 5J).

### Increasing Intracellular PS Increases Toll-like Receptor Activity

To investigate how TAZ knockdown and increases in PS reduce AML stemness and increase differentiation, we characterized the genes that changed after the knockdown of TAZ in OCI-AML2 cells. Among the genes upregulated after TAZ knockdown, we observed a strong enrichment in toll-like receptor (TLR) and other immune activation pathways (false discovery rate [FDR]  $\leq 0.01$ , Figure 6A). TAZ knockdown increased *TLR4* and *TLR8* expression as well as expression of their downstream cytokine mediators *IL6* and *INF $\beta$*  (Figure 6B). Similar changes in *TLR4* and *TLR8* signaling were observed after inhibiting PISD at time points before differentiation was observed (Figure 6C).

Treatment of AML cells with the TLR8 agonist, CL075 increased differentiation and decreased growth of AML cells similar to TAZ knockdown (Figures S6A–S6C). Moreover, the combination of the *TLR8* agonist CL075 with the PISD inhibitor MMV007285 increased expression of *TLR8* more than either drug alone and synergistically decreased growth of AML cells (Figures S6D and S6E). Collectively, these data suggest that the observed TLR activation is functionally important in promoting AML differentiation.


### Increasing Intracellular PS Decreases AML Growth and Stemness In Vivo

Next, we investigated whether altering PS affects AML growth *in vivo*. We knocked down TAZ in 8227 cells as well as primary AML samples (N = 4) and injected control and knockdown cells into the femurs of immunodeficient mice. TAZ knockdown reduced the engraftment potential (Pei et al., 2018) of these primary cells into the mouse marrow (Figures 7A–7E and S7A–S7E).

## Figure 4. TAZ Knockdown Reduces TAZ Activity and Increases Phosphatidylserine, which Are Functionally Important in the Reduction of AML Stemness

- (A and B) The relative MLCL:CL ratio (A) and cardiolipin double bonds (B) in OCI-AML2 cells after TAZ knockdown. Data are mean  $\pm$  SEM (N = 3). \*p  $\leq 0.05$ , \*\*\*p  $\leq 0.001$ , \*\*\*\*p  $\leq 0.0001$  by Student's t test (ML:CL ratio) or two-way ANOVA and post hoc Dunnett's test (cardiolipin double bonds).
- (C) Composition of sphingomyelin (SM), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylethanolamine (PE), and cardiolipin (CL) in OCI-AML2 cells after TAZ knockdown. Data are mean  $\pm$  SEM (N = 3). \*p  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*p  $\leq 0.001$  by two-way ANOVA, and Dunnett's post hoc test.
- (D) Extracellular PS levels in OCI-AML2 cells following TAZ knockdown. Data are mean  $\pm$  SEM of 3 independent experiments.
- (E) PS:PE ratio in OCI-AML2 cells supplemented with 25  $\mu$ M PS or vehicle control. (Vehicle control = 1.0.) Data are mean  $\pm$  SD (n = 4). \*\*\*p  $\leq 0.001$  by Student's t test.
- (F) Cell proliferation of OCI-AML2 cells supplemented with 25  $\mu$ M PS or vehicle control. The relative AUC of viable cell counts over 14 days are shown. Data are relative mean  $\pm$  SD of a representative experiment from 3 independent experiments (Vehicle control = 100%). \*\*p  $\leq 0.01$  by Student's t test.
- (G) Clonogenic growth of OCI-AML2 cells pre-treated with 25  $\mu$ M PS or vehicle control before being seeded in methylcellulose medium without PS. Data are relative mean  $\pm$  SD of a representative experiment from 3 independent experiments (Vehicle control = 100%). \*p  $\leq 0.05$  by Student's t test.
- (H) Clonogenic growth of primary AML cells pre-treated with 25  $\mu$ M PS or vehicle control before seeded in methylcellulose medium without PS. Data are relative mean  $\pm$  SD (n = 2, 0  $\mu$ M = 100%). \*\*p  $\leq 0.01$  by Student's t test.
- (I and J) Engraftment of TEX cells (I) or 8227 cells (J) treated with PS (25  $\mu$ M) in NOD-SCID-GF mice. Bar represents mean. (n = 9–10 mice vehicle control group, n = 9–10 mice). \*\*p  $\leq 0.01$  by Student's t test.
- (K) Engraftment of primary AML cells treated with PS (75  $\mu$ M) or vehicle controls in NOD-SCID-GF mice. Bar represents mean. (n = 10 mice vehicle control group, n = 10 mice PS group.) \*\*\*p  $\leq 0.001$  by Student's t test.
- (L) The role of PS decarboxylase (PISD), where PISD decarboxylates PS to produce PE.
- (M) Immunoblots measuring recombinant PISD protein bound to lipids. Data from 3 independent experiments are shown.
- (N–Q) PISD protein expression (N) and PS:PE ratio (O) of Cas9-OCI-AML2 cells after CRISPR-mediated PISD knockout. Data are mean  $\pm$  SD (n = 4). \*\*\*p  $\leq 0.001$  by Student's t test.
- (P) Proliferation of Cas9-OCI-AML2 cells after CRISPR-mediated PISD knockout. The relative AUC of viable cell counts over 15 days are shown. Data are mean  $\pm$  SD of a representative experiment from three independent experiments (control sgRNA = 100%). \*\*p  $\leq 0.001$  by Student's t test.
- (Q) Clonogenic growth of Cas9-OCI-AML2 cells after CRISPR-mediated PISD knockout. Data are relative mean  $\pm$  SD of a representative experiment from three independent experiments (control sgRNA = 100%). \*\*p  $\leq 0.01$  by Student's t test.

See also Figures S4 and S5.



(legend on next page)

We also knocked out PISD in CAS9-OCI-AML2 cells and monitored their growth, to determine the role of PISD in leukemia propagation *in vivo*. CAS9-OCI-AML2 cells lacking PISD failed to form tumors in SCID mice (Figure 7F).

When we treated primary AML cells with the PISD inhibitor MMV007285 or vehicle control for 48 h and injected an equal number of viable cells into sub-lethally irradiated NOD-SCID mice. Primary AML cells pre-treated with MMV007285 had significantly lower levels of leukemic engraftment compared to primary AML cells pre-treated with the vehicle control (Figure 7G), suggesting that pre-treatment with MMV007285 was sufficient to reduce the leukemia-initiating cell frequency in AML.

Although MMV007285 has a short half-life (Figure S7F), we evaluated the anti-leukemic efficacy and toxicity of systemic treatment with MMV007285 in mouse models of leukemia. SCID mice xenografted with OCI-AML2 cells were treated with MMV007285 or vehicle control. Treatment with MMV007285 delayed the growth of OCI-AML2 cells in mice (Figure 7H) without a more than 10% reduction in body weight (Figure S7G) or alterations in serum chemistry measuring liver, muscle, or renal toxicity (Figure S7G).

Last, we treated mice engrafted with primary AML cells with MMV007285. AML cells were injected intrafemorally into NOD-SCID mice. Eleven days after injection, mice were treated with MMV007285 or vehicle control for 4 weeks. After treatment, levels of AML engraftment in the marrow of the mice was determined by flow cytometry. Treatment of mice with MMV007285 reduced levels of leukemic engraftment compared to controls with no evidence of toxicity (Figures 7I and S7H). We then harvested leukemia cells from the marrow of primary mice and injected these cells into secondary mice. The leukemia grafts from MMV007285-treated mice demonstrated an 80% reduction in engraftment compared to vehicle-treated controls, indicating that MMV007285 inhibits both leukemia propagation and targets leukemia stem cells (Figure 7J).


## DISCUSSION

TAZ is a transacylase responsible for the generation of mature cardiolipin (Lu and Claypool, 2015). Through a CRISPR screen

to identify genes necessary for the growth and viability of AML cells, we identified TAZ as a top hit. Cardiolipin is a mitochondrial phospholipid that undergoes a remodeling process, whereby enzymes such as TAZ alter the acyl chain composition of nascent cardiolipin to produce mature cardiolipin (Lu and Claypool, 2015). Interestingly, both nascent and mature cardiolipin can support oxidative phosphorylation (Baile et al., 2014). The remodeling intermediate MLCL is a byproduct of this reaction, and an optimal MLCL cardiolipin ratio, which is normally very low, is essential for the stability of respiratory chain supercomplexes, which are necessary for the optimal function of the respiratory chain and oxidative phosphorylation (Baile et al., 2014; Cheneval et al., 1983; Claypool and Koehler, 2012; Claypool et al., 2006, 2008; Eble et al., 1990; Lu and Claypool, 2015; Lu et al., 2016; Paradise et al., 2014; Shinzawa-Itoh et al., 2007). Knockdown of TAZ in AML cells increased MLCL levels, cardiolipin acyl chain length, cardiolipin acyl chain double bonds, and decreased total cardiolipin levels, consistent with reductions in TAZ function. However, despite reductions in levels of cardiolipin and acyl chain composition, mitochondrial structure and oxidative phosphorylation were preserved. Therefore, the increase in MLCL and reductions in cardiolipin after inhibiting TAZ were not sufficient to impair mitochondrial function, in keeping with the ability of nascent cardiolipin to support respiratory chain function. Alternatively, MLCL acyltransferase 1 (MLCLAT1) and acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1) also contribute to cardiolipin remodeling, so the redundancy in the cardiolipin acyl chain remodeling pathway potentially maintained sufficient levels of cardiolipin to preserve mitochondrial function (Claypool and Koehler, 2012; Taylor and Hatch, 2003, 2009; Taylor et al., 2012; Xu et al., 2006). However, we did observe an increase in oxidative phosphorylation and a decrease in glycolysis after TAZ knockdown. Thus, while AML cells have an increased reliance on mitochondrial metabolism (Cole et al., 2015; Skrtić et al., 2011; Sriskanthadevan et al., 2015), the reductions in AML growth after TAZ inhibition could not be explained by the changes in glycolysis and oxidative phosphorylation observed, but instead these metabolic changes seem to highlight the effects of differentiation.

### Figure 5. The PISD Inhibitor MMV007285 Reduces AML Growth and Stemness

- (A) Chemical structure of MMV007285.
- (B) PS:PE ratio in OCI-AML2 cells treated with MMV007285 (10  $\mu$ M) or vehicle controls. Data are relative mean  $\pm$  SEM of three independent experiments (0  $\mu$ M = 1.00). \*\* $p$   $\leq$  0.01 by Student's *t* test.
- (C) Cell proliferation of OCI-AML2 cells treated with increasing concentrations of MMV007285 or vehicle control. Relative AUC of viable cell counts over 14 days are shown. Data are the relative mean  $\pm$  SD (0  $\mu$ M = 100%) of one of three independent experiments. \*\*\* $p$   $\leq$  0.001, \*\*\*\* $p$   $\leq$  0.0001 by one-way ANOVA and Dunnett's post hoc test.
- (D) NSE staining of OCI-AML2 cells incubated with MMV007285 or the vehicle control. Data represent relative mean  $\pm$  SEM of three independent experiments (0  $\mu$ M = 1 ABU). \*\* $p$   $\leq$  0.01, \*\*\*\* $p$   $\leq$  0.0001 by Student's *t* test.
- (E) CD11b expression of OCI-AML2 cells incubated with MMV007285 or vehicle control. Data represent relative mean fluorescent intensity (MFI)  $\pm$  SEM of two independent experiments (0  $\mu$ M = 1.0). \*\*\* $p$   $\leq$  0.001 by Student's *t* test.
- (F) Frequency of viable CD34<sup>+</sup>, CD38<sup>-</sup> in MMV007285 and vehicle-treated samples. Data represent relative mean  $\pm$  SEM of three independent experiments (0  $\mu$ M = 100%). \*\* $p$   $\leq$  0.01, \*\*\* $p$   $\leq$  0.001, \*\*\*\* $p$   $\leq$  0.0001 by one-way ANOVA and Dunnett's post hoc test.
- (G) Intracellular PS levels of primary AML cells treated with MMV007285 or the vehicle control. Data represent relative MFI  $\pm$  SD (n = 3, control = 100%). \*\*\* $p$   $\leq$  0.001 by Student's *t* test.
- (H) Clonogenic growth of primary AML cells treated with MMV007285 or vehicle control for 48 h. Data represent mean  $\pm$  SEM of three independent experiments (0  $\mu$ M = 100%). \*\*\*\* $p$   $\leq$  0.0001 by a Student's *t* test.
- (I) Burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte/monocyte (CFU-GM) of normal hematopoietic cells treated with MMV007285 or vehicle control. Data represent mean  $\pm$  SEM of three independent experiments (0  $\mu$ M = 100%).
- (J) Clonogenic growth of bone marrow cells from 21- to 29-week C567BL/6J mice injected with 200 mg/kg of 5-FU and treated with MMV007285 or vehicle control. Data represent mean  $\pm$  SEM of two independent experiments (0  $\mu$ M = 100%).




**Figure 6. TAZ-KD and PISD Inhibitor MMV007285 Activates TLR Signaling**

(A) Pathway enrichment analysis using GSEA, and visualization using Cytoscape EnrichmentMap in OCI-AML2 cells after TAZ knockdown. Circles (nodes) represent pathways, clusters represent biological processes, and lines connect pathways with common genes. Red nodes represent pathways that are up-regulated, and blue nodes represent pathways that are downregulated in TAZ shRNA samples compared to control (FDR  $\leq 0.01$ ). Red arrows indicate upregulated immune pathways.

(B) qRT-PCR of toll-like receptor 4 (*TLR4*), toll-like receptor 8 (*TLR8*), interleukin-6 (*IL6*), interferon-beta (*IFNβ*) in OCI-AML2 cells after TAZ knockdown. Data are relative mean  $\pm$  SD (n = 2–3, control shRNA = 1.0). \*p  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*\*p  $\leq 0.0001$  by one-way ANOVA and Dunnett's post hoc test.

(C) qRT-PCR of toll-like receptor 4 (*TLR4*) and toll-like receptor 8 (*TLR8*), *IL6*, and *IFNβ* in OCI-AML2 cells treated with MMV007285 or vehicle control. Data are mean  $\pm$  SD (n = 2–3, 0  $\mu$ M = 1.0). \*p  $\leq 0.05$ , \*\*p  $\leq 0.01$ , \*\*\*p  $\leq 0.001$ , by Student's t test.

See also Figure S6.



**Figure 7. Increased PS Reduced Leukemia Burden in Xenograft Models of Human Leukemia**

(A) Engraftment of 8227 cells in NOD-SCID-GF mice after TAZ knockdown. Bar represents mean engraftment potential (n = 6 mice/group, control shRNA = 100%), \*\*p ≤ 0.01 by Student's t test.

(legend continued on next page)

Barth syndrome is an inherited disorder due to inactivating mutations in the X-linked *Taz* gene. Individuals with Barth syndrome are viable but have mitochondrial defects that lead to cardiac dysfunction and skeletal muscle weakness (Acehan et al., 2011; Saric et al., 2016). Patients with Barth syndrome also experience transient episodes of neutropenia, but the mechanism for this hematologic toxicity has not been explained to date. We showed that knockdown of TAZ did not affect normal hematopoiesis under basal conditions in mice. Interestingly, when subjected to hematopoietic stress, TAZ knockdown mice had a 40% decrease in ST-HSC and 10% increase in GMP cells, although no change in clonogenic growth was observed. Thus, our results provide a potential mechanism for the transient episodes of neutropenia seen in Barth syndrome. As reported for other conditions that lead to chronic or cyclic neutropenia, repeated episodes of hematopoietic stress can reduce the ST-HSC reserve and produce neutropenia (Bartels et al., 2016; Colijn and Mackey, 2005; Haurie et al., 1998; Mitroulis et al., 2017).

Lipid metabolites are organized in a highly interconnected network, and alterations in levels of one lipid species affect the levels of other intracellular lipids (Köberlin et al., 2015). For example, genetic perturbations in the sphingomyelin synthesis pathway revealed that the synthesis of the glycerophospholipids PS and PE are co-regulated, while PC synthesis is co-regulated with phosphatidylglycerol (Köberlin et al., 2015). Furthermore, ceramide and sphingomyelin synthesis are co-regulated with glycerophospholipids (Köberlin et al., 2015). In this study, we demonstrated that the levels of PS are influenced by cardiolipin metabolism.

Altering cellular lipid composition modulates the activity of some cell signaling pathways including TLR pathways (Huang et al., 2011; Kay and Grinstein, 2013; Köberlin et al., 2015). We have shown that increasing PS levels activates TLR4 and TLR8 signaling. Interestingly, TLR signaling is a known regulator of hematopoietic and AML differentiation (Hayashi et al., 2010; Ignatz-Hoover et al., 2015; Köberlin et al., 2015; Megias et al., 2012; Nagai et al., 2006). The stimulation of TLR4 drives myeloid differentiation during emergency hematopoiesis in response to infection (Hayashi et al., 2010; Megias et al., 2012; Nagai et al., 2006). Also, the TLR8 agonist R848 promotes AML differentiation and reduces tumor burden both *in vivo* and *in vitro* (Ignatz-Hoover et al., 2015).

Increasing intracellular levels of PS by supplementing cells with this phospholipid decreased AML growth and stemness, and thus phenocopied the effects of TAZ inhibition. These results are consistent with a prior study where PS supplementation promoted the osteogenic differentiation of mesenchymal stromal

cells (Xu et al., 2013). We also increased intracellular PS and reduced AML stemness by genetically or chemically inhibiting PISD. As a chemical approach, we used the PISD inhibitor MMV007285 (Choi et al., 2016; Lucantoni et al., 2013). MMV007285 was initially identified through a screen for inhibitors of malarial PISD, but our results show that MMV007285 also targets the mammalian form of PISD. Reducing levels of PISD in breast cancer cells induced their differentiation (Keckesova et al., 2017). Thus, similar to breast cancer inhibiting PISD in AML reduced stemness and promoted differentiation and could be a therapeutic strategy for AML. Although a useful tool to study PISD *in vitro*, MMV007285 has a short half-life when administered systemically to mice. Therefore, developing more potent and stable PISD inhibitors based on other scaffolds is a priority to fully assess the efficacy and toxicity of PISD inhibition *in vivo* and evaluate PISD as a potential therapeutic target for AML.

In summary, our study suggests that phospholipid composition is critical for leukemia, stemness, initiation, and propagation. Although AML is genetically diverse, phospholipid metabolism may be amendable for therapeutic exploitation.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Human Cell Lines
  - Animals
  - TAZ-KD Induction in iDOX-Taz-KD Mice
  - Primary AML and Normal Hematopoietic Cells
  - Primary AML Cell Cultures for Transduction
- METHODS DETAILS
  - Plasmids
  - Lentiviral Packing
  - CAS9-OCI-AML2 Cell Line Generation
  - CRISPR Screen
  - MAGeCk Analysis
  - Viral Infection
  - Mitochondrial Protein Lysates
  - Whole Cell Protein Lysates
  - Immunoblotting
  - Basal Apoptosis
  - Cell Cycle Analysis
  - Colony Formation Assays

(B–E) Engraftment of primary AML cells from patients 100565 (B), 120541 (C), 120287 (D), and 120860 (E) in NOD-SCID mice after TAZ knockdown. Bar represents mean engraftment potential ( $n = 6–8$  mice/group, control shRNA = 100%), \*\* $p \leq 0.01$ , \*\*\*\* $p \leq 0.0001$  by Student's *t* test.

(F) Tumor growth of Cas9-OCI-AML2 cells after PISD knockout. Data represent mean  $\pm$  SD ( $n = 8$  mice/group). \*\*\*\* $p \leq 0.0001$  by two-way ANOVA and Bonferroni's post hoc test.

(G) Primary AML cell engraftment in NOD-SCID after pre-treatment *in vitro* of cells for 48 h with 12.5  $\mu$ M of MMV00728. Data represent mean  $\pm$  SD ( $n = 10$  mice/group). \*\*\* $p \leq 0.01$  by Student's *t* test.

(H) Tumor growth of OCI-AML2 cells xenografts into SCID mice treated with 300 mg/kg of MMV007285 or vehicle control twice daily for 5 days/week orally ( $n = 10$  mice/group). Data represent mean  $\pm$  SD, \*\* $p \leq 0.01$ , \*\*\*\* $p \leq 0.0001$  by two-way ANOVA and Bonferroni's post hoc test.

(I) Engraftment of primary AML cells in NOD-SCID mice treated once daily with MMV007285 (150 mg/kg orally) for 5 days/week Bar represents mean ( $n = 9$  control group,  $n = 10$  MMV007285 group). \*\*\* $p \leq 0.001$ , as determined by Student's *t* test

(J) Secondary engraftment of primary AML cells from (I). Bar represents mean ( $n = 7$  mice/group). \*\*\* $p \leq 0.001$ , as determined by Student's *t* test. See also Figure S7.

- RNA-Sequencing
- Differential Gene Expression Analysis
- Pathway Analysis
- TCGA Unsupervised Clustering
- LSC+/LSC- Signature Analysis
- DMAP Signature Analysis
- PERT deconvolution analysis
- Non-Specific Esterase Staining
- NSE Staining Analysis Using ImageJ
- Cell Surface Phenotype of OCI-AML2
- RNA Isolation and Quantitative Reverse Transcriptase-Real Time Polymerase Chain Reaction
- Lipid Extraction Protocols
- UHPLC/MS Characterization of MLCL and CL
- Densitometric Analysis of Phospholipids
- Densitometric Phospholipid Analysis
- Quantification of Extracellular PS
- PS Quantification by Confocal Microscopy
- PS Quantification Using ImageJ
- Sensitivity to Extrinsic Apoptosis
- Seahorse
- Cellular Reactive Oxygen Species
- Mitochondrial Mass
- Live Imaging
- Aspect Ratio
- Electron Microscopy
- Lipid-Protein Overlay Assay
- Lipid Supplementation and Growth Analysis
- MMV Treatment and Growth Analysis
- 8227 Flow Cytometry
- PS Quantification by Flow Cytometry
- MMV and CL075 Synergism Studies
- Animal Studies
- Calculation of Engraftment Potential
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AVAILABILITY**

#### SUPPLEMENTAL INFORMATION

Supplemental Information can be found with this article online at <https://doi.org/10.1016/j.stem.2019.02.020>.

#### ACKNOWLEDGMENTS

We thank Jill Flewelling (Princess Margaret Cancer Center) for administrative assistance. We also thank The Center of Applied Genomics at Sick Kids for performing RNA sequencing and analysis, as well as the Microscopy Imaging Laboratory for performing electron microscopy. This work was supported by the Canadian Institutes of Health Research, the Ontario Institute of Cancer Research with funding provided by the Ontario Ministry of Research and Innovation, the Princess Margaret Cancer Centre Foundation, the Ministry of Long Term Health and Planning in the Province of Ontario, and the NIH (R01HL108882 and R01GM111548 to S.M.C.). A.D.S. holds the Barbara Baker Chair Leukemia and Related Diseases. A.K.S. holds the Fredrick Banting and Charles Best Canada Graduate Scholarships-Doctoral Award from the Canadian Institute of Health as well as the McLaughlin Award from the University of Toronto. M.X. holds the Princess Margaret Hospital Postdoctoral Fellowship and Lady Tata Foundation Postdoctoral Fellowship.

#### AUTHOR CONTRIBUTIONS

Conception and Design, Collection, and/or Assembly of Data, Data Analysis, Interpretation, Manuscript Writing, A.K.S. and M.X.; Collection and/or Assem-

bly of Data, Data Analysis, and Interpretation, A.D.S.; Conception and Design, Financial Support, Collection and/or Assembly of Data, Data Analysis and Interpretation, Manuscript Writing, Final Approval of the Manuscript, J.J.A.H., V.A.F., Z.H., V.V., G.W.X., R.H., S.K., N.M., X.W., M.G., D.J., Y.J., T.K., M.M., D.S., G.T., R.C.-W., J.R.H., H.L.Y., C.S., Z.K., A.A., R.A., A.G., S.M.C., R.B., M.L., S.C., D.D.D., M.D.M., G.D.B., K.D.S., and P.L.

#### DECLARATION OF INTERESTS

A.D.S. has received honorariums from Novartis, Jazz, and Otsuka Pharmaceuticals and research support from Medivir AB and Takeda. A.D.S. owns stock in Abbvie Pharmaceuticals.

Received: June 12, 2018

Revised: December 19, 2018

Accepted: February 27, 2019

Published: March 28, 2019

#### REFERENCES

- Acehan, D., Vaz, F., Houtkooper, R.H., James, J., Moore, V., Tokunaga, C., Kulik, W., Wansapura, J., Toth, M.J., Strauss, A., and Khuchua, Z. (2011). Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. *J. Biol. Chem.* **286**, 899–908.
- Baile, M.G., Sathappa, M., Lu, Y.W., Pryce, E., Whited, K., McCaffery, J.M., Han, X., Alder, N.N., and Claypool, S.M. (2014). Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast. *J. Biol. Chem.* **289**, 1768–1778.
- Bartels, M., Murphy, K., Rieter, E., and Bruin, M. (2016). Understanding chronic neutropenia: life is short. *Br. J. Haematol.* **172**, 157–169.
- Borisy, A.A., Elliott, P.J., Hurst, N.W., Lee, M.S., Lehar, J., Price, E.R., Serbedzija, G., Zimmermann, G.R., Foley, M.A., Stockwell, B.R., and Keith, C.T. (2003). Systematic discovery of multicomponent therapeutics. *Proc. Natl. Acad. Sci. USA* **100**, 7977–7982.
- Bradley, R.M., Mardian, E.B., Bloemberg, D., Aristizabal Henao, J.J., Mitchell, A.S., Marvyn, P.M., Moes, K.A., Stark, K.D., Quadrilatero, J., and Duncan, R.E. (2017). Mice Deficient in *lysophosphatidic acid acyltransferase delta (Lpaatδ)/acylglycerophosphate acyltransferase 4 (Agpat4)* Have Impaired Learning and Memory. *Mol. Cell. Biol.* Published online October 27, 2017. <https://doi.org/10.1128/MCB.00245-17>.
- Chan, S.M., Thomas, D., Corces-Zimmerman, M.R., Xavy, S., Rastogi, S., Hong, W.J., Zhao, F., Medeiros, B.C., Tyvoll, D.A., and Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. *Nat. Med.* **21**, 178–184.
- Cheneval, D., Müller, M., and Carafoli, E. (1983). The mitochondrial phosphate carrier reconstituted in liposomes is inhibited by doxorubicin. *FEBS Lett.* **159**, 123–126.
- Choi, J.Y., Kumar, V., Pachikara, N., Garg, A., Lawres, L., Toh, J.Y., Voelker, D.R., and Ben Mamoun, C. (2016). Characterization of Plasmodium phosphatidylserine decarboxylase expressed in yeast and application for inhibitor screening. *Mol. Microbiol.* **99**, 999–1014.
- Churchward, M.A., Brandman, D.M., Rogasevskaia, T., and Coorsen, J.R. (2008). Copper (II) sulfate charring for high sensitivity on-plate fluorescent detection of lipids and sterols: quantitative analyses of the composition of functional secretory vesicles. *J. Chem. Biol.* **1**, 79–87.
- Claypool, S.M., and Koehler, C.M. (2012). The complexity of cardiolipin in health and disease. *Trends Biochem. Sci.* **37**, 32–41.
- Claypool, S.M., McCaffery, J.M., and Koehler, C.M. (2006). Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins. *J. Cell Biol.* **174**, 379–390.
- Claypool, S.M., Oktay, Y., Boontheung, P., Loo, J.A., and Koehler, C.M. (2008). Cardiolipin defines the interactome of the major ADP/ATP carrier protein of the mitochondrial inner membrane. *J. Cell Biol.* **182**, 937–950.
- Cole, A., Wang, Z., Coyaud, E., Voisin, V., Gronda, M., Jitkova, Y., Mattson, R., Hurren, R., Babovic, S., Maclean, N., et al. (2015). Inhibition of the

- Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. *Cancer Cell* 27, 864–876.
- Colijn, C., and Mackey, M.C. (2005). A mathematical model of hematopoiesis: II. Cyclical neutropenia. *J. Theor. Biol.* 237, 133–146.
- Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C., and Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc. Natl. Acad. Sci. USA* 111, 2548–2553.
- Eble, K.S., Coleman, W.B., Hantgan, R.R., and Cunningham, C.C. (1990). Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by <sup>31</sup>P nuclear magnetic resonance spectroscopy. *J. Biol. Chem.* 265, 19434–19440.
- Folch, J., Lees, M., and Sloane Stanley, G.H. (1957). A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* 226, 497–509.
- Gonzalez, F., Schug, Z.T., Houtkooper, R.H., MacKenzie, E.D., Brooks, D.G., Wanders, R.J., Petit, P.X., Vaz, F.M., and Gottlieb, E. (2008). Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. *J. Cell Biol.* 183, 681–696.
- Gonzalez, F., D'Aurelio, M., Boutant, M., Moustapha, A., Puech, J.P., Landes, T., Arnauné-Pelloquin, L., Vial, G., Taleux, N., Slomianny, C., et al. (2013). Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. *Biochim. Biophys. Acta* 1832, 1194–1206.
- Gu, W., Gaeta, X., Sahakyan, A., Chan, A.B., Hong, C.S., Kim, R., Braas, D., Plath, K., Lowry, W.E., and Christofk, H.R. (2016). Glycolytic Metabolism Plays a Functional Role in Regulating Human Pluripotent Stem Cell State. *Cell Stem Cell* 19, 476–490.
- Hart, T., Chandrashekar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015). High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. *Cell* 163, 1515–1526.
- Haurie, C., Dale, D.C., and Mackey, M.C. (1998). Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. *Blood* 92, 2629–2640.
- Hayashi, E.A., Granato, A., Paiva, L.S., Bertho, A.L., Bellio, M., and Nobrega, A. (2010). TLR4 promotes B cell maturation: independence and cooperation with B lymphocyte-activating factor. *J. Immunol.* 184, 4662–4672.
- Huang, B.X., Akbar, M., Kevala, K., and Kim, H.Y. (2011). Phosphatidylserine is a critical modulator for Akt activation. *J. Cell Biol.* 192, 979–992.
- Ignatz-Hoover, J.J., Wang, H., Moreton, S.A., Chakrabarti, A., Agarwal, M.K., Sun, K., Gupta, K., and Wald, D.N. (2015). The role of TLR8 signaling in acute myeloid leukemia differentiation. *Leukemia* 29, 918–926.
- Jan, M., Snyder, T.M., Corces-Zimmerman, M.R., Vyas, P., Weissman, I.L., Quake, S.R., and Majeti, R. (2012). Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. *Sci. Transl. Med.* 4, 149ra118.
- Karasuyama, H., and Melchers, F. (1998). Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. *Eur. J. Immunol.* 18, 97–104.
- Kay, J.G., and Grinstein, S. (2013). Phosphatidylserine-mediated cellular signaling. *Adv. Exp. Med. Biol.* 991, 177–193.
- Keckesova, Z., Donaher, J.L., De Cock, J., Freinkman, E., Lingrell, S., Bachovchin, D.A., Bieri, B., Tischler, V., Noske, A., Okondo, M.C., et al. (2017). LACTB is a tumour suppressor that modulates lipid metabolism and cell state. *Nature* 543, 681–686.
- Köberlin, M.S., Snijder, B., Heinz, L.X., Baumann, C.L., Fauster, A., Vladimer, G.I., Gavin, A.C., and Superti-Furga, G. (2015). A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses. *Cell* 162, 170–183.
- Kuntz, E.M., Baquero, P., Michie, A.M., Dunn, K., Tardito, S., Holyoake, T.L., Helgason, G.V., and Gottlieb, E. (2017). Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. *Nat. Med.* 23, 1234–1240.
- Lagadinou, E.D., Sach, A., Callahan, K., Rossi, R.M., Neering, S.J., Minhajuddin, M., Ashton, J.M., Pei, S., Grose, V., O'Dwyer, K.M., et al. (2013). BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. *Cell Stem Cell* 12, 329–341.
- Lechman, E.R., Gentner, B., Ng, S.W., Schoof, E.M., van Galen, P., Kennedy, J.A., Nucera, S., Ciceri, F., Kaufmann, K.B., Takayama, N., et al. (2016). miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. *Cancer Cell* 29, 214–228.
- Li, W., Xu, H., Xiao, T., Cong, L., Love, M.I., Zhang, F., Irizarry, R.A., Liu, J.S., Brown, M., and Liu, X.S. (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biol.* 15, 554.
- Lu, Y.W., and Claypool, S.M. (2015). Disorders of phospholipid metabolism: an emerging class of mitochondrial disease due to defects in nuclear genes. *Front. Genet.* 6, 3.
- Lu, Y.W., Galbraith, L., Herndon, J.D., Lu, Y.L., Pras-Raves, M., Vervaart, M., Van Kampen, A., Luyf, A., Koehler, C.M., McCaffery, J.M., et al. (2016). Defining functional classes of Barth syndrome mutation in humans. *Hum. Mol. Genet.* 25, 1754–1770.
- Lucantoni, L., Duffy, S., Adjalley, S.H., Fidock, D.A., and Avery, V.M. (2013). Identification of MMV malaria box inhibitors of plasmodium falciparum early-stage gametocytes using a luciferase-based high-throughput assay. *Antimicrob. Agents Chemother.* 57, 6050–6062.
- Malhotra, A., Edelman-Novemsky, I., Xu, Y., Plesken, H., Ma, J., Schlame, M., and Ren, M. (2009). Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. *Proc. Natl. Acad. Sci. USA* 106, 2337–2341.
- McCracken, M.N., George, B.M., Kao, K.S., Marjon, K.D., Raveh, T., and Weissman, I.L. (2016). Normal and Neoplastic Stem Cells. *Cold Spring Harb. Symp. Quant. Biol.* 81, 1–9.
- Megias, J., Yáñez, A., Moriano, S., O'Connor, J.E., Gozalbo, D., and Gil, M.L. (2012). Direct Toll-like receptor-mediated stimulation of hematopoietic stem and progenitor cells occurs in vivo and promotes differentiation toward macrophages. *Stem Cells* 30, 1486–1495.
- Mitroulis, I., Chen, L.S., Singh, R.P., Kourtzelis, I., Economopoulou, M., Kajikawa, T., Troullinaki, M., Ziogas, A., Ruppova, K., Hosur, K., et al. (2017). Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. *J. Clin. Invest.* 127, 3624–3639.
- Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepper, A.M., Hinkle, G., Piquani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 124, 1283–1298.
- Nagai, Y., Garrett, K.P., Ohta, S., Bahrun, U., Kouro, T., Akira, S., Takatsu, K., and Kincade, P.W. (2006). Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. *Immunity* 24, 801–812.
- Ng, S.W., Mitchell, A., Kennedy, J.A., Chen, W.C., McLeod, J., Ibrahimova, N., Arruda, A., Popescu, A., Gupta, V., Schimmer, A.D., et al. (2016). A 17-gene stemness score for rapid determination of risk in acute leukaemia. *Nature* 540, 433–437.
- Nicolini, F.E., Cashman, J.D., Hogge, D.E., Humphries, R.K., and Eaves, C.J. (2004). NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. *Leukemia* 18, 341–347.
- Novershtern, N., Subramanian, A., Lawton, L.N., Mak, R.H., Haining, W.N., McConkey, M.E., Habib, N., Yosef, N., Chang, C.Y., Shay, T., et al. (2011). Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell* 144, 296–309.
- Paradies, G., Paradies, V., Ruggiero, F.M., and Petrosillo, G. (2014). Cardiolipin and mitochondrial function in health and disease. *Antioxid. Redox. Signal.* 20, 1925–1953.
- Pei, S., Minhajuddin, M., Adane, B., Khan, N., Stevens, B.M., Mack, S.C., Lai, S., Rich, J.N., Inguva, A., Shannon, K.M., et al. (2018). AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. *Cell Stem Cell* 23, 86–100.

- Qiao, W., Quon, G., Csaszar, E., Yu, M., Morris, Q., and Zandstra, P.W. (2012). PERT: a method for expression deconvolution of human blood samples from varied microenvironmental and developmental conditions. *PLoS Comput. Biol.* *8*, e1002838.
- Saric, A., Andreau, K., Armand, A.S., Møller, I.M., and Petit, P.X. (2016). Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. *Front. Genet.* *6*, 359.
- Shinzawa-Itoh, K., Aoyama, H., Muramoto, K., Terada, H., Kurauchi, T., Tadehara, Y., Yamasaki, A., Sugimura, T., Kurono, S., Tsujimoto, K., et al. (2007). Structures and physiological roles of 13 integral lipids of bovine heart cytochrome c oxidase. *EMBO J.* *26*, 1713–1725.
- Shlush, L.I., Mitchell, A., Heisler, L., Abelson, S., Ng, S.W.K., Trotman-Grant, A., Medeiros, J.J.F., Rao-Bhatia, A., Jaciw-Zurakowsky, I., Marke, R., et al. (2017). Tracing the origins of relapse in acute myeloid leukemia to stem cells. *Nature* *547*, 104–108.
- Simpson, C.D., Hurren, R., Kasimer, D., MacLean, N., Eberhard, Y., Ketela, T., Moffat, J., and Schimmer, A.D. (2012). A genome wide shRNA screen identifies  $\alpha/\beta$  hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance. *Apoptosis* *17*, 666–678.
- Skrtić, M., Sriskanthadevan, S., Jhas, B., Gebbia, M., Wang, X., Wang, Z., Hurren, R., Jitkova, Y., Gronda, M., Maclean, N., et al. (2011). Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. *Cancer Cell* *20*, 674–688.
- Soustek, M.S., Falk, D.J., Mah, C.S., Toth, M.J., Schlame, M., Lewin, A.S., and Byrne, B.J. (2011). Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. *Hum. Gene Ther.* *22*, 865–871.
- Sriskanthadevan, S., Jeyaraju, D.V., Chung, T.E., Prabha, S., Xu, W., Skrtić, M., Jhas, B., Hurren, R., Gronda, M., Wang, X., et al. (2015). AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. *Blood* *125*, 2120–2130.
- Stefanyk, L.E., Coverdale, N., Roy, B.D., Peters, S.J., and LeBlanc, P.J. (2010). Skeletal muscle type comparison of subsarcolemmal mitochondrial membrane phospholipid fatty acid composition in rat. *J. Membr. Biol.* *234*, 207–215.
- Sykes, D.B., Kfoury, Y.S., Mercier, F.E., Wawer, M.J., Law, J.M., Haynes, M.K., Lewis, T.A., Schajnovitz, A., Jain, E., Lee, D., et al. (2016). Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. *Cell* *167*, 171–186.
- Taylor, W.A., and Hatch, G.M. (2003). Purification and characterization of monolysocardiolipin acyltransferase from pig liver mitochondria. *J. Biol. Chem.* *278*, 12716–12721.
- Taylor, W.A., and Hatch, G.M. (2009). Identification of the human mitochondrial linoleoyl-coenzyme A monolysocardiolipin acyltransferase (MLCL AT-1). *J. Biol. Chem.* *284*, 30360–30371.
- Taylor, W.A., Mejia, E.M., Mitchell, R.W., Choy, P.C., Sparagna, G.C., and Hatch, G.M. (2012). Human trifunctional protein alpha links cardiolipin remodeling to beta-oxidation. *PLoS ONE* *7*, e48628.
- Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O.M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. *Cell Rep.* *17*, 1193–1205.
- Warner, J.K., Wang, J.C., Takenaka, K., Doulatov, S., McKenzie, J.L., Harrington, L., and Dick, J.E. (2005). Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. *Leukemia* *19*, 1794–1805.
- Xu, Y., Malhotra, A., Ren, M., and Schlame, M. (2006). The enzymatic function of tafazzin. *J. Biol. Chem.* *281*, 39217–39224.
- Xu, C., Zheng, Z., Fang, L., Zhao, N., Lin, Z., Liang, T., Zhai, Z., and Zhou, J. (2013). Phosphatidylserine enhances osteogenic differentiation in human mesenchymal stem cells via ERK signal pathways. *Mater. Sci. Eng. C* *33*, 1783–1788.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse monoclonal anti-TAZ (F-7)	Santa Cruz Biotechnology	Cat# Sc-365810 RRID: AB_10842049
Rabbit polyclonal anti-PISD	Proteintech Group	Cat# 16401-1-AP, RRID:AB_2186673
Rabbit monoclonal PTSS1 antibody	Abcam	Cat# ab157222
Rabbit monoclonal PSS2 antibody	Abcam	Cat# ab183504
Rabbit monoclonal anti-citrate synthase	Abcam	Cat# ab129095
Mouse monoclonal anti- beta-Actin (AC-15)	Santa Cruz Biotechnology	Cat# sc-69879, RRID:AB_1119529
Rabbit polyclonal anti-beta Tubulin (H-235)	Santa Cruz Biotechnology	Cat# sc-9104, RRID:AB_2241191
Sheep Anti-Mouse IgG, Whole Ab ECL Antibody, HRP Conjugated	GE Healthcare	Cat# NA931, RRID:AB_772210
Donkey Anti-Rabbit IgG, Whole Ab ECL Antibody, HRP Conjugated	GE Healthcare	Cat# NA934, RRID:AB_772206
BB515 Rat Anti-Mouse Ly-6A/E	BD Biosciences	Cat# 565397
Pe/Cy7 Rat anti-mouse CD117 (c-Kit)	BioLegend	Cat# 105814 RRID: AB_2131136
PE Rat anti-mouse CD150 (SLAM)	BioLegend	Cat# 115904 RRID: AB_313683
APC Hamster anti-mouse CD48	ThermoFisher Scientific	Cat# 17-0481-82 RRID: AB_469408
APC/Cy7 Rat anti-mouse CD16/32	BioLegend	Cat# 101328 RRID: AB_2104158
eFluor 450 Rat anti-mouse CD34	ThermoFisher Scientific	Cat# 48-0341-82 RRID: AB_2043837
APC Mouse anti-human CD11b	BD Biosciences	Cat# 340937
APC Mouse anti-human CD14	BD Biosciences	Cat# 555399
CD34	BD Biosciences	Cat# 348053, RRID:AB_2228982
CD38	BD Biosciences	Cat# 342371, RRID:AB_400453
CD122	Lab Stock	N/A
<b>Biological Samples</b>		
Human AML Patient Samples	Leukemia Biobank, Princess Margaret Hospital	N/A
Normal Peripheral Blood Stem Cells (PBSC's)	Leukemia Biobank, Princess Margaret Hospital	N/A
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Iscove's Modification Dulbecco's Modification Eagle's Medium (IMDMEM)	Wisent	Cat# 319-701-CL
RPMI 1640	Wisent	Cat# 350-700-CL
Alpha MEM	Lab Stock	N/A
MyeloCult H5100	STEMCELL Technologies	Cat# 05150
X-VIVO 10 Chemically Defined, Serum-free Hematopoietic Cell Medium	Lonza	Cat# 04-380Q
Dulbecco's Modification Eagle's Medium (DMEM)	Wisent	Cat# 319-005-CL
Fetal Bovine Serum	Sigma-Aldrich	Cat# F1051
Recombinant Human SCF Protein (TEX)	R&D Systems	255-sc/cf., R&D,
Recombinant Human IL-3 Protein (TEX)	R&D Systems	203-IL
L-Glutamine 200mM (TEX)	ThermoFisher Scientific	Cat# 25030081
Recombinant Human IL-3 (8227, and Primary Sample Transductions)	PeproTech	Cat# 200-03
Recombinant Human SCF (78227, and Primary Sample Transductions)	PeproTech	Cat# 300-07

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Recombinant Human Flt3-Ligand (8227, and Primary Sample Transductions)	PeproTech	Cat# 300-19
Recombinant Human TPO (8227, and Primary Sample Transductions)	PeproTech	Cat# 300-18
Recombinant Human IL-6 (8227, and Primary Sample Transductions)	PeproTech	Cat# 200-06
BIT 9500 Serum Substitute (8227, and Primary Sample Transductions)	STEMCELL Technologies	Cat# 09500
Human GM-CSF, premium grade (primary samples)	Miltenyi Biotec	Cat# 130-093-866
Human IL-6 (primary samples)	Miltenyi Biotec	Cat# 130-095-365
Human Flt3-Ligand (primary samples)	Miltenyi Biotec	Cat# 130-096-479
Human IL-7 (primary samples)	Miltenyi Biotec	Cat# 130-095-363
Granulocyte colony stimulating factor (G-CSF), [Filgrastim]	Amgen Canada	CAS#121181-53-1
Puromycin HCL	Sigma-Aldrich	Cat# P8833
Protamine Sulfate	MP Biomedicals	Cat#194729
Laemmli buffer	Lab Stock	N/A
RIPA buffer	Lab Stock	N/A
TBS (10X)	Wisent	Cat# 311-030-LL
Thermo Scientific Pierce ECL western blotting substrate	ThermoFisher Scientific	Cat# PI32106
Annexin V –FITC Reagent	CEDARLANE, BioVision	Cat# 1001-1000
Propidium Iodide	CEDARLANE, BioVision	Cat# 1056-1
Annexin V Binding Buffer	Lab Stock	N/A
Sodium Fluoride	Sigma-Aldrich	Cat# 919
Rodent Chow with 625mg doxycycline/kg chow	Ren's Pets Depot	Cat# 58MY-1811541
Red Blood Cell Lysing Buffer Hybri-Max	Sigma-Aldrich	Cat# R7757
Lineage Cell Depletion Kit mouse	MACS Miltenyi Biotec	Cat# 130-090-858
autoMACs Rinsing Solution	MACS Miltenyi Biotec	Cat# 130-091-222
MACs BSA Stock Solution	MACS Miltenyi Biotec	Cat# 130-091-376
7AAD	BD Biosciences	Cat# 559925
UltraComp eBeads	affymetrix eBioscience	Cat# 01-2222-42
mSCF	Miltenyi Biotec	Cat# 130-101-697
mIL-6	Miltenyi Biotec	Cat# 130-096-683
mIL-3 Conditioned Media	<a href="#">Karasuyama and Melchers, 1998</a>	N/A
5-Fluorouracil	Sigma-Aldrich	Cat# F6627-10G
Chloroform (UHPLC/MS)	Fisher Scientific	Cat# C6074
Methanol CHROMASOLV, Riedel-de Haen (UHPLC/MS)	Fisher Scientific	Cat# 60046513
Sodium-Phosphate Monobasic Anhydrous (UHPLC/MS)	Fisher Scientific	Cat# BP329-500
Alfa Aesar Acetonitrile (UHPLC/MS)	Fisher Scientific	Cat# AA47138K7
Isopropanol, Optima (UHPLC/MS)	Fisher Scientific	Cat# A4614
Formic Acid, Optima (UHPLC/MS)	Fisher Scientific	Cat# A11750
Amonium Formate (UHPLC/MS)	Sigma-Aldrich	Cat# 70221-100G-F
Standard (UHPLC/MS): 14:0 Cardiolipin	Avanti, Polar Lipids	Cat# 710332C
Human Recombinant <i>Killer</i> TRAIL	Alexis Biochemicals	Cat# 201-123-C500
Cyclohexamide	Sigma-Aldrich	Cat# C7698
Oligomycin	Sigma-Aldrich	Cat# 75351
FCCP	Cayman Chemical	Cat# 15218

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Corning Cell-Tak	FisherScientific	Cat# C354240
Seahorse XF assay medium	Agilent	Cat# 102365-100
Paraformaldehyde	Electron Microscopy Sciences	Cat# RT19200
70% Glutaraldehyde	Electron Microscopy Sciences	Cat# 16360
Sodium Phosphate Monobasic monohydrate (NaH <sub>2</sub> PO <sub>4</sub> ·H <sub>2</sub> O Buffer)	Sigma-Aldrich	Cat# S9638
Sodium Phosphate Dibasic (Na <sub>2</sub> H <sub>2</sub> P <sub>0</sub> <sub>4</sub> , Buffer)	Lab Stock	Cas# 7558-79-4
1N Sodium Hydroxide [NaOH]	Lab stock	Cas# 1310-73-2
Osmium tetroxide [OsO <sub>4</sub> ]	Electron Microscopy Sciences	Cat# RT19100
Embed-812 kit	Electron Microscopy Sciences	Cat# 14120
300 Mesh Copper grids	Electron Microscopy Sciences	Cat# G300H-Cu
Uranyl Acetate	Electron Microscopy Sciences	Cat# 22400
Lead Nitrate [Pb(NO <sub>3</sub> ) <sub>2</sub> ] for staining for electron microscopy	Electron Microscopy Sciences	Cat# RT17900
Sodium Citrate [Na <sub>3</sub> C <sub>6</sub> H <sub>5</sub> O <sub>7</sub> ·2H <sub>2</sub> O] for staining	Electron Microscopy Sciences	Cat# RT21140
MitoTracker Red CMXRos	ThermoFisher Scientific	Cat# M7512
Poly-L-lysine	Sigma-Aldrich	Cat#P4707
Chloroform (CHCl <sub>3</sub> , Spot Densitometry)	Sigma-Aldrich	Cat# 34854
Methanol (CH <sub>3</sub> OH, Spot Densitometry)	Sigma-Aldrich	Cat# 34860
Acetic Acid (C <sub>3</sub> H <sub>6</sub> O, Spot Densitometry)	Canadawide Scientific	Cat# CWA0302-4
Standard (Spot Densitometry): Sphingomyelin	Sigma-Aldrich	Cat# S0756
Standard (Spot Densitometry): L- $\alpha$ -Phosphatidylcholine	Sigma-Aldrich	Cat# P3556
Standard (Spot Densitometry): L- $\alpha$ -Phosphatidyl-L-serine	Sigma-Aldrich	Cat# P0474
Standard (Spot Densitometry): L- $\alpha$ -Phosphatidylinositol	Sigma-Aldrich	Cat# P6636
Standard (Spot Densitometry): L- $\alpha$ -Phosphatidylethanolamine	Sigma-Aldrich	Cat# P7943
Standard (Spot Densitometry): Cardiolipin Sodium Salt from Bovine Heart	Sigma-Aldrich	Cat# C0563
Copper (II) sulfate pentahydrate (Spot Densitometry)	Sigma-Aldrich	Cat# C-6283
O-Phosphoric Acid (Spot Densitometry)	Fisher Scientific	Cat# A242-212
PBS (Spot Densitometry)	Sigma-Aldrich	Cat# P3813
H <sub>2</sub> O (Spot Densitometry)	Fisher Scientific	Cat# 2745
HPTLC plates (Spot Densitometry)	Sigma-Aldrich	Cat# 1.05633.0001
Chloroform	Lab Stock	Cas# 67-66-3
HPLC methanol	Sigma-Aldrich	Cat# 646377
Dimethyl sulfoxide (DMSO)	Sigma-Aldrich	Cat# D8418
Tween 80	Sigma-Aldrich	Cat# P4780
Propylene Glycol (PEG)	Sigma-Aldrich	Cat# P4347
Methanol	BioShop Canada	Cat# MET302
Soy PS	Avanti Polar Lipids	Cat# 870336P
Soy PE	Avanti Polar Lipids	Cat# 840024P
Egg Lyso PE	Avanti Polar Lipids	Cat# 860081P
Saponin	Sigma-Aldrich	47036-50G-F
Bovine Serum Albumin	Sigma-Aldrich	Cat# A9647
16% paraformaldehyde (CAT#15710)	Electron Microscopy Sciences	Cat# 15710
AnnexinV Alexa-647	ThermoFisher Scientific	Cat# A23204
ProLong Gold Antifade Mountant	ThermoFisher Scientific	Cat# P36934

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
SuperScript IV Reverse Transcriptase	ThermoFisher Scientific	Cat# 18090050
7-chloro-N-(4-ethoxyphenyl)-4-quinolinamine (MMV007285)	This paper	Jae-Yeon <a href="#">Choi et al., 2016</a>
CL075	TOCRIS	Cat# 6142
Formic acid (Pharmacokinetic Studies)	Sigma-Aldrich	Cat# 33015
CellTiter 96 Aqueous MTS Reagent Powder	Promega	Cat# G1111
RetroNectin Recombinant Human Fibronectin Fragment	Takara	Cat# T100A
Acetonitrile, Optima, Fisher Chemical (Pharmacokinetic Studies)	ThermoFisher Scientific	Cat# A996-4
<b>Critical Commercial Assays</b>		
E.N.Z.A Plasmid Midi Kit	Omega BIO-TEK	Cat# D6904-04
Cytochrome c Releasing Apoptosis Assay Kit	abcam	Cat# ab65311
$\alpha$ -Naphthyl Acetate (Non-Specific Esterase)	Sigma-Aldrich®	Cat# 91A-1KT
Protein Assay Dye	Bio-Rad	Cat# 5000006
DC Protein Assay kit II	Bio-Rad	Cat#5000112
MethoCult H4100	STEMCELL Technologies	Cat# 04100
MethoCult H4434	STEMCELL Technologies	Cat# 04434
MethoCult GF M3534	STEMCELL Technologies	Cat# 03534
Bioanalyzer RNA Analysis Kit	Agilent Technologies	Cat# 5067-1511
KAPA Library Complete Quantification Kit for ABI Prism genetic analyzer and Illumina	KAPABiosystems	Cat# KK4835
Agilent High Sensitivity DNA Kit	Agilent Technologies	Cat# 5067-4626
NEBNext Ultra Directional RNA Library Prep Kit for Illumina	New England BioLabs	Cat# E7420S
HiSeq SBS kit V4 250 cycle kit	Illumina	Cat# FC-401-4003
Carboxy-H2DCFDA	ThermoFisher Scientific	Cat# C400
RNeasy Plus Mini Kit	QIAGEN	Cat# 74134
Power SYBR Green PCR Master Mix	ThermoFisher Scientific	Cat# 4367659
Lenti-X Concentrator	Takara	Cat# 631231
Lipid strips	Echelon Biosciences	Cat# P-6002
Fatty acid-free Bovine Serum Albumin	Sigma-Aldrich®	Cat# A7030
PISD recombinant protein	OriGene	Cat# TP761730
<b>Deposited Data</b>		
AML2 gene expression after TAZ-KD	This paper	GEO: GSE107045
<b>Experimental Models: Cell Lines</b>		
Human: OCI-AML2	Wang C et al., 1989	N/A
Human: TEX	<a href="#">Warner et al., 2005</a>	N/A
Human: K562	ATCC	Cat# CCL-243
Human: U937	ATCC	Cat# CRL-1593
8227 cells	<a href="#">Lechman et al., 2016</a>	N/A
293T/17	ATCC	Cat# CRL-11268
<b>Experimental Models: Organisms/Strains</b>		
Mouse: NOD.Cg-Prkdc <sup>scid</sup> Il2rg <sup>tm1Wjl</sup> Tg(CMV-IL3,CSF2,KITLG)1Eav/MloYsZJ (NOD-SCID-GF)	<a href="#">Nicolini et al., 2004</a>	N/A
Mouse: B6.Cg-Gt(ROSA)26Sor <sup>tm37(H1/tetO-RNAi:Taz)Arte</sup> /ZkhJ doxycycline-Inducible-TAZ-Knockdown (iDOX-Taz-KD)	<a href="#">Acehan et al., 2011</a>	N/A
Mouse: C57BL/6J	Jackson Laboratory	Cat# 000664; RRID: IMSR_JAX:000664
Mouse: NOD.CB17-Prkdc <sup>scid</sup> /J (NOD-SCID)	Jackson Laboratory	Cat# 001303

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse: Prkdc <sup>scid</sup> (SCID)	In house	RRID: IMSR_ARC: SCID
<b>Oligonucleotides</b>		
Primers for <i>TAZ</i> , <i>PISD</i> , <i>18srRNA</i> , <i>LYZ</i> , iDOX- <i>Taz</i> -shRNA, <i>ND1</i> , <i>HGB</i> , <i>TLR4</i> , <i>TLR8</i> , <i>IL6</i> , and <i>IFN<math>\beta</math></i>	See Table	Table S4
sgRNAs targeting <i>TAZ</i> , <i>PISD</i> , and control sequences	See Table	Table S6
shRNAs targeting <i>TAZ</i> , and control sequences	See Table	Table S6
<b>Recombinant DNA</b>		
pCMV-R8.74psPAX2 Packaging Plasmid	Moffat et al., 2006	N/A
VSV-G/pMD2.G Envelope Plasmid	Moffat et al., 2006	N/A
pLKO.1-Puro-shRNA lentiviral plasmid	Moffat et al., 2006	N/A
Cas9-2A-Blast lentiviral plasmid	Hart et al., 2015	N/A
pLCKO-Puro-sgRNA lentiviral plasmid	Hart et al., 2015	Addgene #73311
pRS19-Puro-GFP-shRNA lentiviral plasmid	Chan et al., 2015	N/A
TKO CRISPR library V1	Hart et al., 2015	N/A
pLenti-EF1a-C-Myc-DDK-IRES-Bsd plasmid	OriGene	Cat# PS100085
<b>Software and Algorithms</b>		
MAGEck	Li et al., 2014	<a href="https://sourceforge.net/projects/mageck/">https://sourceforge.net/projects/mageck/</a>
ImageJ	NIH	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>
GraphPad Prism	GraphPad Software version 6.03 for Windows, GraphPad Software, La Jolla California USA	<a href="https://www.graphpad.com/">https://www.graphpad.com/</a>
FLOWJO	FlowJo v 7.7.1, TreeStar, Ashland Oregon USA	<a href="https://www.flowjo.com/">https://www.flowjo.com/</a>
Xcalibur v.2.1	Thermo-Fisher Scientific	Part# XCALI-97213
Chromeleon Xpress v.7.2	Thermo-Fisher Scientific	Cat# CHROMELEON7
NIST MS Search v.2.0	NIST	<a href="https://chemdata.nist.gov/mass-spc/ms-search/">https://chemdata.nist.gov/mass-spc/ms-search/</a>
FastQC v.0.11.2	Babraham Institute	<a href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>
Trim Galore v. 0.4.0.	Babraham Institute	<a href="http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</a>
FastQ-Screen v.0.4.3	Babraham Institute	<a href="http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/">http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/</a>
RSeQC v. 2.3.7		<a href="http://rseqc.sourceforge.net/">http://rseqc.sourceforge.net/</a>
Tophat v. 2.0.11	John's Hopkins University	<a href="https://ccb.jhu.edu/software/tophat/index.shtml">https://ccb.jhu.edu/software/tophat/index.shtml</a>
htseq- v.0.6.1p2	Simon Anders	<a href="https://www-huber.embl.de/users/anders/HTSeq/doc/overview.html">https://www-huber.embl.de/users/anders/HTSeq/doc/overview.html</a>
DESeq v.1.18.0	Bioconductor	<a href="http://bioconductor.org/packages/release/bioc/html/DESeq.html">http://bioconductor.org/packages/release/bioc/html/DESeq.html</a>
edgeR, R package, v.3.16.5 (Differential Gene Expression Analysis, Control shRNA Vs. TAZ-KD)	Bioconductor	<a href="http://www.bioconductor.org/packages/release/bioc/html/edgeR.html">http://www.bioconductor.org/packages/release/bioc/html/edgeR.html</a>
edgeR, R package, v.3.28.21 (Differential Gene Expression Analysis, LSC- versus LSC+, TCGA clusters)	Bioconductor	<a href="http://bioconductor.org/packages/release/bioc/html/edgeR.html">http://bioconductor.org/packages/release/bioc/html/edgeR.html</a>
Gene Set Enrichment Analysis Software	Broad Institute	<a href="http://software.broadinstitute.org/gsea/msigdb/">http://software.broadinstitute.org/gsea/msigdb/</a>
Cytoscape 3.6.1	The Cytoscape Consortium	<a href="http://www.cytoscape.org/?gclid=CjwKCAjw_tTXBRBsEiwArqXyMp1y9jXNftKoksBpO7Q2BCKzWsvEGPteq7VRCpoVHH22tEsWgCnb7BoCnL4QAvD_BwE">http://www.cytoscape.org/?gclid=CjwKCAjw_tTXBRBsEiwArqXyMp1y9jXNftKoksBpO7Q2BCKzWsvEGPteq7VRCpoVHH22tEsWgCnb7BoCnL4QAvD_BwE</a>
EnrichmentMap 3.1	The Cytoscape Consortium	<a href="https://enrichmentmap.readthedocs.io/en/docs-3.1/">https://enrichmentmap.readthedocs.io/en/docs-3.1/</a>
AutoAnnotate 1.2.	The Cytoscape Consortium	<a href="http://apps.cytoscape.org/apps/autoannotate">http://apps.cytoscape.org/apps/autoannotate</a>

(Continued on next page)

### Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
affy, R package, affy_1.38.1	Bioconductor	<a href="https://www.bioconductor.org/packages/release/bioc/html/affy.html">https://www.bioconductor.org/packages/release/bioc/html/affy.html</a>
sva, R package, sva_3.6.0	Bioconductor	<a href="http://bioconductor.org/packages/release/bioc/html/sva.html">http://bioconductor.org/packages/release/bioc/html/sva.html</a>
Other		
LSC+ and LSC- Geneset	<a href="#">Ng et al., 2016</a>	GEO: GSE76008
TCGA Repository	National Cancer Institute	<a href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</a>
DMAP	<a href="#">Novershtern et al., 2011</a>	GEO: GSE24759
Bader Lab Database	This paper	<a href="http://baderlab.org/GeneSets">http://baderlab.org/GeneSets</a> , version from September 2017

### CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and request for resources and reagents should be directed and will be fulfilled by the Lead Contact, Dr. Aaron Schimmer ([aaron.schimmer@uhn.ca](mailto:aaron.schimmer@uhn.ca)).

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### Human Cell Lines

OCI-AML2, and K562 cells were maintained in IMDM (Iscove's modified Dulbecco's medium), supplemented with 10% FBS (fetal bovine serum), 100 units/mL penicillin and 100  $\mu$ g/mL of streptomycin. TEX cells obtained from John Dick's lab ([Warner et al., 2005](#)) were cultured in IMDM, with 20% FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100  $\mu$ g/mL of streptomycin, 20 ng/mL stem cell factor (SCF), and 2 ng/mL interleukin-3 (IL-3). U-937 cell were maintained in RPMI 1640 medium, with 10% FBS, 100 units/mL penicillin and 100  $\mu$ g/mL of streptomycin. K562 and U-937 cells were authenticated via STR profiling. 8227 cells were also provided by John Dick's lab (Princess Margaret Cancer Centre, University Health Network, Toronto, Canada) ([Lechman et al., 2016](#)) and were cultured in X-VIVO-10, with 20% bovine serum albumin-insulin-transferrin (BIT), Fms-related tyrosine kinase 3 ligand (Flt3-L, 50 ng/ml), interleukin-6 (IL-6, 10 ng/ml), SCF (50 ng/ml), thrombopoietin (TPO, 25 ng/ml), IL-3 (10 ng/ml), granulocyte colony-stimulating factor (G-CSF, 10 ng/ml). Lentiviral packing cells (293T) were cultured in DMEM with 10% FCS for seeding, and DMEM with 10% FCS, 100 units/mL penicillin and 100  $\mu$ g/mL of streptomycin, as well as 1% BSA for harvesting of virus. All cell lines were maintained at 37°C, supplemented with 5% CO<sub>2</sub>. The sex and age of the patients from whom the cell lines were generated are indicated in [Table S3](#).

#### Animals

Six-twelve week Male or female immunodeficient NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup> Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NOD-SCID-GF) mice used to transplant TEX and 8227 cells were obtained from Dr. Connie J. Eaves and bred in our facility ([Nicolini et al., 2004](#)). Eight-twelve week female immunodeficient NOD.CB17-Prkdc<sup>scid</sup>/J (NOD-SCID) and 6-8 week immunodeficient male Prkdc<sup>scid</sup> (SCID) mice, used for the transplantation of primary AML and OCI-AML2 cells respectively were obtained from the Ontario Cancer Institute. Mice were randomly assigned to each experimental group.

Immunocompetent B6.Cg-Gt(ROSA)26Sor<sup>tm37(H1/tetO-RNAi:Taz)Arte</sup>/ZkhuJ doxycycline-Inducible-TAZ-Knockdown (iDOX-Taz-KD) transgenic mice were acquired from Dr. Zaza Khuchua, at the University of Cincinnati. In collaboration with TaconicArtemis GmbH Dr. Khuchua generated the iDOX-Taz-KD mice, in a C57BL/6J genetic background as previously described ([Acehan et al., 2011](#)). iDOX-Taz-KD transgenic mice transferred to our facility, were backcrossed with female immunocompetent C57BL/6J mice for 7-10 generations. To maintain iDOX-Taz-KD transgenic mice on a C57BL/6J genetic background, iDOX-Taz-KD male mice were bred with either wild-type littermates or C57BL/6J female mice. iDOX-Taz-KD mice were weaned onto a standard chow diet and genotyped for the iDOX-Taz-shRNA transgene by PCR of the tail genomic DNA ([Table S4](#)). Note that, iDOX-Taz-KD transgenic mice were born viable at the expected Mendelian ratio and displayed normal fertility. Litter mates were randomly assigned to experimental groups. Twenty-one to twenty-nine week C57BL/6J mice were used to assess the effect MMV007285 has on hematopoietic cells subjected to stress.

During all experiments, the weights of the mice were approximately 18-30 g with no animals losing greater than 10% body weight. All animals were housed in microisolator cages with temperature-controlled conditions under a 12-hour light/dark cycle with free access to drinking water, and food. Only one experimental procedure was performed in each mouse, and all mice used were drug naive prior to the experiment. Furthermore, all animal studies were performed in accordance with the Ontario Cancer Institute Animal Use Protocol (AUP): # 1251.33 (NOD-SCID-GF, NOD-SCID, and SCID) and AUP # 2244.12 (iDOX-Taz-KD transgenic mice).

### TAZ-KD Induction in iDOX-Taz-KD Mice

TAZ-knockdown was induced by feeding 7.6-14.3 week old iDOX-Taz-KD transgenic mice with DOX-containing chow (625 mg/kg chow), formulated by Purina Mills, for 12.9-19.4 weeks. Non-transgenic littermates were fed DOX-containing chow and used as wild-type (WT) controls.

### Primary AML and Normal Hematopoietic Cells

Primary human AML samples were obtained from peripheral blood or the bone marrow of consenting male or female AML patients, with a malignant cell frequency of 80% among mononuclear cells. Differential density centrifugation was used to isolate AML cells. Peripheral blood stem cells (PBSCs) were obtained from healthy consenting male or female volunteers, donating PBSCs for allogeneic stem cell transplantation. PBSCs were isolated by G-CSF stimulation, and leukopheresis. Both primary AML cells, and PBSCs were frozen in alpha MEM + 5% FBS or 90% FBS + 15U/mL of heparin + 10% DMSO. The University Health Network institutional review boards approved the collection and use of human tissue for this study (Research Ethics Board protocol #15-9324). As per regulation, all specimens were de-identified. Each experiment was performed using a single aliquot from a donor. Information about the patients who were the source of the cells are indicated in [Table S5](#).

### Primary AML Cell Cultures for Transduction

Cells were thawed in a 37°C water bath, washed once in media composed of IMDM 10% FBS, 100 units/mL penicillin, and 100 µg/mL of streptomycin. Primary AML cells were resuspended in X-VIVO 10 supplemented with 20% BIT, 50 ng/ml Flt3-L, 10 ng/mL IL-6, 50 ng/mL SCF, 25 ng/mL TPO, 10 ng/mL IL-3, 10 ng/mL G-CSF at a concentration of  $5.0 \times 10^5$  cells/mL before being transduced.

## METHODS DETAILS

### Plasmids

The 90K gRNA library developed in Hart et al., 2015 was obtained from the Moffat lab. Whereas, the TAZ, PISD, and control guide RNA (sgRNA) oligonucleotides were synthesized and cloned into the pLCKO lentiviral vector using the BspAI/BfuAI sites as described previously ([Hart et al., 2015](#)). The coding sequence of sgRNA's targeting TAZ (gene id: 6901), PISD (gene id: 23761), and the LacZ genes (Control) are listed in [Table S6](#).

For the transduction of AML cell lines, the TAZ shRNA constructs in the hairpin-pLKO.1 vector were purchased from Sigma-Aldrich® as glycerol bacterial stocks. The coding sequence of shRNAs targeting TAZ (accession number NM\_000116), and the control shRNA targeting the GFP sequence (GFP, accession number clontechGfp\_587s1c1) are listed in [Table S6](#).

To transduce 8227 cell and primary AML patient samples, TAZ shRNA sequences were first modified in order to be cloned into the hairpin-pRS19 vector using the restriction enzyme BsbI. The coding sequence of shRNAs targeting TAZ (accession number NM\_000116), and the control shRNA non-targeting sequence are listed in [Table S6](#).

The PISD gene (Accession number NM\_014338) from the Myc-DDK-tagged PISD ORF (OriGene #RC200269) was cloned into the pLenti-EF1a-C-Myc-DDK-IRES-Bsd plasmid (OriGene, #PS100085), using restriction enzymes AclI and MluI.

All sgRNA, shRNA, and overexpression plasmids were validated by Sanger sequencing before its use in downstream experiments.

### Lentiviral Packing

For library virus production lentivirus was made in a 175 cm<sup>2</sup> flask format, by transfecting  $11 \times 10^6$  packaging cells (293T) with a three-plasmid system (lentiviral pLCKO vector containing the library, packing plasmid with: gag, pol, and rev genes, and envelope plasmid) ([Hart et al., 2015](#); [Moffat et al., 2006](#)).

sgRNA and shRNA plasmids used in AML cell lines were isolated using the E.N.Z.A® Plasmid Midi Kit system (Omega bio-tek, GA, USA) from glycerol bacteria stocks, and then quantified by the NanoDrop (ThermoScientific, MA, USA) spectrophotometer. Lentivirus was made in a 25 cm<sup>2</sup> flask format, by 293T cells with a three-plasmid system (hairpin-pLKO.1 vector/ guide-pLCKO vector, packing plasmid with: gag, pol, and rev genes, and envelope plasmid) ([Cole et al., 2015](#); [Simpson et al., 2012](#)).

Whereas, cloned shRNA plasmids used in primary AML patient samples were isolated using the E.N.Z.A® Plasmid Midi Kit system (Omega bio-tek, GA, USA), and then quantified by the NanoDrop (ThermoScientific, MA, USA) spectrophotometer. Lentivirus was made in a 175 cm<sup>2</sup> flask format, by transfecting 293T cells with a three-plasmid system (hairpin-pRS19 vector, packing plasmid with: gag, pol, and rev genes, and envelope plasmid) ([Cole et al., 2015](#); [Simpson et al., 2012](#)). The virus was concentrated using the Lenti-X Concentrator as per manufacturer's instructions.

### CAS9-OCI-AML2 Cell Line Generation

CAS9-OCI-AML2 cells were generated by adapting a method previously described ([Hart et al., 2015](#)). We first infected OCI-AML2 cells with virus containing a CAS9-2A-Blasticidin expressing cassette (Addgene plasmid#73310) and then selected with blasticidin (10 µg/mL) for six days. After selection period CAS9-OCI-AML2 clones were sorted by manual seeding at a concentration of 0.4 cells/well in 96-well plates. Independent clones were isolated, and the CAS9 mRNA levels for each clone was quantified by RT-qPCR. The clone with the highest level of CAS9 mRNA (designated clone 7), was further analyzed by immunoblotting for CAS9 protein levels. Subsequently, the Cas9-expressing clonal population was subject to another round of single cell cloning procedures described above. The clone (designated clone 7.2) from the second round of selection was then characterized by

immunoblotting for Cas9 protein expression and selected for screening as well as the TAZ, and PS decarboxylase (PISD) knockout studies as described below.

### **CRISPR Screen**

To identify gRNA that reduced the growth and viability of AML cells, we performed a pooled lentiviral gRNA screen cells as described previously (Hart et al., 2015). CAS9-OCI-AML2 cells were transduced with a pooled lentiviral library consisting of 91,320 sgRNAs in barcoded lentiviral vectors targeting 17,232 nuclear-encoded genes. The day after transduction, cells were treated with puromycin (2  $\mu\text{g}/\text{mL}$ ) to select transduced cells. Resistant clones were passaged at regular intervals (3-4 days). Cells were harvested at 3 and 17 days post-transduction. Genomic DNA was extracted from cell pellets obtained on day 3 as well as day 17 and sequenced on an Illumina NextSeq500 (Illumina, CA, USA). shRNA depletion was characterized by MAGeCk analysis as described below.

### **MAGeCk Analysis**

sgRNA sequences were first extracted from FASTQ files by trimming and then aligned to a reference library via Bowtie. Mapped sgRNA counts for samples were analyzed using MAGeCk 0.5.5, using default parameters (Li et al., 2014). Essential genes were identified at a FDR < 5%, by comparing of D17 sgRNA to D0 sgRNA.

### **Viral Infection**

#### **CRISPR-sgRNA Knockout**

$1.0 \times 10^6$  CAS9-OCI-AML2 cells were centrifuged and resuspended in 3 mL of medium containing 5  $\mu\text{g}/\text{mL}$  of protamine sulfate. 1 mL of virus was added to cells, followed by a 24-hour incubation (37°C, 5% CO<sub>2</sub>). On the following day, cells were centrifuged and washed, then resuspended in fresh medium with puromycin (1.5  $\mu\text{g}/\text{mL}$ ). After at least 3 days of selection, equal numbers of cells were plated for growth assay, and counted by trypan blue exclusion staining for a period of 12-15 days post-transduction. To confirm knockout, 5-20  $\times 10^6$  cells were collected at day 8 post-transduction for immunoblot analysis, as described in the mitochondria protein lysate, and immunoblotting sections below.

#### **shRNA knockdown of AML Cell Lines**

Lentiviral infections with shRNA constructs were performed as previously described in Cole et al., 2015.  $5 \times 10^6$  cells were centrifuged and resuspended in 5 mL of medium containing 5  $\mu\text{g}/\text{mL}$  of protamine sulfate. 2 mL of virus was added to cells, followed by a 24-hour incubation (37°C, 5% CO<sub>2</sub>). On the following day, cells were centrifuged washed, and resuspended in fresh medium with puromycin (1.5  $\mu\text{g}/\text{mL}$  for OCI-AML2, 2  $\mu\text{g}/\text{mL}$  for TEX, K562, and U-937 cells). After 3 days of selection, equal numbers of cells were plated for growth assay, and counted by trypan blue exclusion staining for a period of 12 days post-transduction. To confirm target knockdown, 5-20  $\times 10^6$  cells were collected at day 4 post-transduction for immunoblot analysis, as described in mitochondria protein lysate and immunoblotting sections below.

#### **shRNA knockdown of Primary AML Samples**

Lentiviral infections with shRNA constructs were performed as previously described (Chan et al., 2015). Wells in a 24-well non-tissue-culture-treated plate were coated with 500  $\mu\text{l}$  of RetroNectin® (20  $\mu\text{g}/\text{mL}$  in PBS) per well for 2 hours at room temperature. The wells were blocked with 1 mL of 2% BSA (W/V) for 30 minutes at room temperature. The BSA solution was then aspirated, and concentrated lentiviral particles in HBBS with 25 mM HEPES were added to each well at a volume of 0.5 mL. The plate was then centrifuged at 3,000 rpm for 5 hours at room temperature to promote the attachment of lentiviral particles to RetroNectin®. After aspirating 0.4 mL of the viral supernatant,  $5 \times 10^5$  cells were added to each well in 1 mL of X-VIVO 10 (20% BIT, 50 ng/ml Flt3-L, 10 ng/mL IL6, 50 ng/mL SCF, 25 ng/mL TPO, 10 ng/mL IL3, 10 ng/mL G-CSF). The plate was then centrifuged again at 1,300 rpm for 10 minutes at room temperature to promote the interaction between the cells and lentiviral particles, and then transferred to a 37°C incubator to initiate lentiviral infection. Twenty-four hours afterward, the cells were resuspended in fresh media at a concentration of  $1 \times 10^6$  cells/mL and seeded in a 24-well plate at 1 mL per well. TAZ Knockdown was confirmed by quantitative reverse transcriptase-real time polymerase chain reaction (qRT-PCR) 5-7 days after transduction, as described in the qRT-PCR section.

#### **PISD Overexpression**

OCI-AML2 cells were transduced with lentiviral particles containing PISD or control vector sequences, and then selected with 10  $\mu\text{g}/\text{mL}$  blasticidin for 8 days. After selection, PISD or empty vector overexpressing cells were transduced with TAZ or control shRNA constructs as described in shRNA knockdown of AML cell lines section. Eleven days after transduction with the PISD vector sequence PISD overexpression was confirmed by qRT-PCR, and cell phenotype was characterized by non-specific esterase staining, as described in the qRT-PCR and non-specific esterase sections below.

### **Mitochondrial Protein Lysates**

Mitochondrial lysates were made to quantify TAZ, using the cytochrome c releasing apoptosis kit (Abcam, Cambridge, UK), as per manufacturer's instructions, with minor modifications. We harvested confluent cells and froze these cells on dry ice. Cell pellets (10-20  $\times 10^6$  cells) were then thawed on ice and lysed in distilled water containing protease inhibitors, by hypotonic shock for 15 minutes at 4°C. The Cytosolic Extraction Buffer Mix containing DTT and protease inhibitors were added to the cell lysate, and samples were then centrifuged at 800 g at 4°C for 20 minutes. The supernatant containing mitochondria was collected and centrifuged at 10,000 g for 30 minutes at 4°C. Next, the supernatant was discarded, and the mitochondrial pellet was resuspended in ice-cold Mitochondrial Extraction Buffer, with DTT and protease inhibitors. Finally, mitochondria were lysed by adding 2X Laemmli buffer.

The protein concentration in mitochondrial lysates was quantified using the DC protein determination kit (Bio-Rad, CA, USA) before immunoblotting.

### Whole Cell Protein Lysates

For all other immunoblots whole cell lysates were used. To make whole cell lysates, cells ( $5 \times 10^6$ ) were washed with PBS followed by cell lysis in RIPA buffer. Protein concentration was measured by Bradford method (Protein assay dye, Bio-Rad, CA, USA).

### Immunoblotting

Equal amounts of protein were loaded and fractionated on 10%–12% SDS-polyacrylamide gels. Proteins were separated on SDS-PAGE and transferred to nitrocellulose membranes or PVDF prior to antibody treatment. Blots were blocked with 5% milk TBST then incubated overnight with an appropriate primary antibody. Membranes were then blocked with 5% milk TBST, and further probed using an appropriate secondary antibody conjugated to HRP, and then developed using Enhanced chemiluminescence (ECL) detection (ThermoFisher Scientific, MA, USA). The antibodies used for immunoblotting can be found in the key resource table.

### Basal Apoptosis

OCI-AML2 cells were transduced with shRNA in lentiviral vectors targeting TAZ or control sequences. Seven days after transduction, cells were harvested, and cell death was measured by flow cytometry with annexin V fluorescein isothiocyanate (FITC) and propidium iodide (PI) R- Phycoerythrin (PE, Biovision Research Products, CA, USA) staining according to the manufacturer's instructions. Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and frequency of annexin V, PI negative cells were quantified with the FlowJo software (TreeStar, OR, USA)

### Cell Cycle Analysis

OCI-AML2 cells were transduced with shRNA in lentiviral vectors targeting TAZ or control sequences. Seven days after transduction, cells were harvested, washed with cold PBS, and fixed in absolute ethanol and PBS (80% ethanol, 20% PBS) for a minimum of one hour. Afterward, cells were washed in cold PBS, and treated with 5  $\mu\text{g}/\text{mL}$  of DNase-free RNase A (Invitrogen, CA, USA) at 37°C for 30 minutes, then incubated in PBS containing 5  $\mu\text{g}/\text{mL}$  of propidium iodide (PI) for 5–10 minutes at room temperature. DNA content was measured using flow cytometry (FACs CANTO, BD, FL, USA) and analyzed with FlowJo software (TreeStar, OR, USA).

### Colony Formation Assays

#### Leukemia Cell Lines

Five (TAZ knockdown OCI-AML2, and TEX cells) or nine (PISD knockout CAS9-OCI-AML2 cells) days after transduction cells were plated at equal concentrations (CAS9-OCI-AML2 and OCI-AML2 = 750 cells; TEX cells = 2,000) in duplicate 35mm dishes. (Nunclon, Rochester, USA) to a final volume of 1 mL/dish in MethoCult H4100 media (StemCell Technologies, BC, Canada) supplemented with 30% FCS (CAS9-OCI-AML2 and OCI-AML2) or MethoCult H4100 media (StemCell Technologies, BC, Canada) supplemented with 30% FCS, 20 ng/mL SCF, and 2 ng/mL IL-3 (TEX cells). After incubating the dishes for 5 (CAS9-OCI-AML2), 7 (OCI-AML2), or 10 (TEX) days at 37°C, 5% CO<sub>2</sub> with 95% humidity, the number of colonies containing 10 or more cells were counted on an inverted microscope. The mean of the duplicate plates for each condition are presented. During serial re-plating colonies were removed from MethoCult by vortexing and washing in PBS, cells were counted and then re-plated in MethoCult every 5 (PISD knockout CAS9-OCI-AML2 cells) or 7 (TAZ knockdown TEX cells) days. The mean of the duplicate plates for each condition are presented.

To assess clonogenic growth after PS treatment, OCI-AML2 cell were pre-treated with 25  $\mu\text{M}$  of PS or the vehicle control for 9 days. Afterward, treated OCI-AML2 cells were plated at equal volumes in duplicate 35mm dishes. (Nunclon, NY, USA) to a final volume of 1 mL/dish in MethoCult H4100 media (StemCell Technologies, BC, Canada) supplemented with 30% FCS without PS. After 5 days of incubation at 37°C, 5% CO<sub>2</sub> with 95% humidity, the number of colonies containing 10 or more cells were counted on an inverted microscope. The mean of the duplicate plates for each condition are presented.

#### Primary Samples

Fresh AML mononuclear cells and normal peripheral blood stem cells (PBSCs) ( $4 \times 10^5$  AML cells,  $2 \times 10^5$  PBSCs) were incubated with MMV007285, PS or vehicle control for 48 hours in MyelocultH5100, supplemented with 100 ng/mL SCF, 10 ng/mL Flt3-L, 20 ng/mL IL-7, 10 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, 20 ng/mL GM-CSF. Treated PBSC's or AML patient samples were plated in MethoCult H4434 medium (StemCell Technologies, BC, Canada). After incubating the dishes for 7 days (AML) or 2 weeks (normal hematopoietic cells) at 37°C with 5% CO<sub>2</sub> and 95% humidity, AML colonies containing 10 or more cells and PBSC colonies containing more than 50 cells were counted. The mean of duplicate plates for each condition are presented.

To assess the clonogenic growth of mouse hematopoietic progenitor cells after TAZ knockdown and hematopoietic stress, 40000 bone marrow cells cells/ml/dish from WT or TAZ-KD mice treated with 0 or 200 mg/Kg of 5-FU were plated on MethoCult GF M3534, and incubated at 37°C, 5% CO<sub>2</sub> with 95% humidity, 15 days after 5-FU treatment. Six days after, colonies containing 50 or more cells were enumerated. During serial re-plating, colonies were removed from MethoCult GF M3534 by vortexing and washing in PBS. Cells were counted and 40000 cells/ml/dish replated on MethoCult GF M3534. After 6 days in culture, colonies containing 50 cells or more cells were enumerated. The mean of the duplicate plates for each condition are presented.

The effect MMV007285 has on hematopoietic cells subjected to stress was characterized by incubating 160000 bone marrow cells isolated from C57BL/6J mice 15 days after treatment with 0 or 200 mg/Kg in StemSpan SFEM media (50 ng/mL mSCF, 50 ng/mL

mIL6, 1:320 mIL3 conditioned media) containing 0 or 12.5  $\mu$ M MMV007285 for 72 hours. After pre-treatment the cells were washed and plated on MethoCult GF M3534 with 0 or 12.5  $\mu$ M of MMV007285, then incubated at 37°C, 5% CO<sub>2</sub> with 95% humidity for 6 days. Finally, colonies containing 50 or more cell were enumerated. The mean of the duplicate plates for each condition are presented.

### RNA-Sequencing

Total RNA was isolated from OCI-AML2 cells using the RNeasy Plus Mini Kit (QIAGEN, Hilden, Germany) 7 days after transduction with shRNA targeting TAZ or control sequences. The experimental design consisted of 2 biological replicates of control cells and 2 biological replicates of TAZ knockdown samples. Quality of total RNA samples were checked on an Agilent Bioanalyzer 2100 RNA Nano chip (CA, USA) following Agilent Technologies' recommendation. Concentration was measured by Qubit RNA HS Assay on a Qubit fluorometer (ThermoFisher Scientific, MA, USA). RNA library preparation was performed following the NEBNext Ultra Directional Library (MA, USA) Preparation Protocol. Briefly, 800 ng of total RNA was used as the input material and enriched for poly-A mRNA, fragmented into the 200-300-bases range for 4 minutes at 94°C and converted to double stranded cDNA, end-repaired and adenylated at the 3' to create an overhang A to allow for ligation of Illumina adapters with an overhang T; library fragments were amplified under the following conditions: initial denaturation at 98°C for 10 s, followed by 13 cycles of 98°C for 10 s, 60°C for 30 s and 72°C for 30 s, and finally an extension step for 5 minutes at 72°C; at the amplification step, each sample were amplified with a different barcoded adapters to allow for multiplex sequencing. One  $\mu$ l of the final RNA libraries was loaded on a Bioanalyzer 2100 DNA High Sensitivity chip (Agilent Technologies, CA, USA) to check for size; RNA libraries were quantified by qPCR using the KAPA Library Quantification Illumina/ABI Prism Kit protocol (MA, USA). Libraries were pooled in equimolar quantities and paired-end sequenced on 1 lane of a High Throughput Run Mode flowcell with the V4 sequencing chemistry on an Illumina HiSeq 2500 platform (CA, USA) following Illumina's recommended protocol to generate paired-end reads of 126-bases in length. RNA-sequencing data was used to perform differential gene expression analysis as described below.

### Differential Gene Expression Analysis

Prior to analysis, read adapters and low quality ends were removed using Trim Galore v. 0.4.0. Reads were aligned against hg19 using Tophat v. 2.0.11. Read counts per gene were obtained through htseq-count v.0.6.1p2 in the mode "intersection\_nonempty." After removing genes whose cpm (counts per million reads) were less than 0.5 in at least one sample, edgeR R package v.3.16.5 was used to normalize the data using the TMM (trimmed mean of M values) method and to estimate differential expression by applying the generalized linear model likelihood ratio test between the control OCI-AML2 samples and the TAZ-KD OCI-AML2 samples. A score that ranks genes in TAZ knockdown samples from the most upregulated to the most downregulated compared to control shRNA samples was calculated using the formula  $-\log_{10}(\text{pvalue}) * \text{sign}(\log\text{FC})$ . Pathway, LSC+/LSC- signature, DMAP signature, and PERT deconvolution analyses was performed using the differential expression data generated.

### Pathway Analysis

The rank list genes generated for TAZ knockdown and control shRNA samples was used for Gene set enrichment analysis (GSEA) with a setting of 1000 permutations, and default parameters. The pathway database from the Bader lab (<http://baderlab.org/GeneSets>, version of September 2017) which contains the Gene Ontology, Biological Process, as well as Msigdb-c2 and -c3, IOB, NetPath, HumanCyc, Reactome and Panther was used. Results were visualized in Cytoscape 3.6.1 using EnrichmentMap 3.1, clustered and annotated using AutoAnnotate 1.2. Cluster labels were manually edited for clarity. Pathway analysis was validated by measuring mRNA levels of *TLR4*, *TLR8*, *IL6*, and *IFN $\beta$*  in TAZ knockdown or MMV treated samples, by qRT-PCR as described in the qRT-PCR section.

### TCGA Unsupervised Clustering

The TCGA AML RNaseq data were retrieved from the GDC portal (<https://portal.gdc.cancer.gov/>). Read counts were normalized using the TMM method in the edgeR R package. The TCGA samples were hierarchically clustered using the Ward linkage method and Euclidean distance on the basis of the scaled  $\log_2(\text{CPM})$  of the 5,334 genes with standard deviation > 1. AU (approximately unbiased) cluster probability, computed by multiscale bootstrap resampling, was calculated using the R package pvclust.

### LSC+/LSC- Signature Analysis

Illumina beadchip transcriptomics data containing LSC+ and LSC- sorted AML fractions were obtained from the Gene Expression Omnibus data portal (GSE76008) (Ng et al., 2016) and differential expression between LSC+ and LSC- fractions was calculated using a moderated t test available in the limma R package 3.28.21, incorporating array batch effects into the linear model. First, the 500 most highly upregulated genes in TAZ knockdown and control shRNA samples were compared to normalized gene expression of LSC+/LSC- fractions, then subsequently visualized using the heatmap.2 function in R by setting row normalization as true. In addition, the top upregulated in the LSC+ fractions to top downregulated in comparison to LSC- fractions was scored using the formula  $-\log_{10}(\text{pvalue}) * \text{sign}(\log\text{FC})$ . The 400 highest scoring in LSC+ and the 400 highest scoring LSC- genes were used as signature gene set for LSC+ and LSC- samples respectively. Then gene set enrichment analysis (GSEA) (Broad Institute, MA, USA) with 1000 permutations and default parameters was used to measure the enrichment of genes upregulated in TAZ knockdown and control samples in the LSC+ or LSC- gene signatures.

### DMAP Signature Analysis

Changes in gene expression after TAZ knockdown were mapped to the Gene Expression Omnibus dataset GSE24759 (DMAP) (Novshtern et al., 2011), containing Affymetrix GeneChip HT-HG\_U133A Early Access Array gene expression data of 20 distinct hematopoietic cell states. GSE24759 data were background corrected using Robust Multi-Array Average (RMA), quantile normalized using the `expresso` function of the `affy` Bioconductor package (`affy_1.38.1`, R 3.0.1), array batch corrected using the `ComBat` function of the `sva` package (`sva_3.6.0`), and then standardized using Z score for each gene across samples. Bar graphs were created by selecting genes that were up- (top 500) TAZ knockdown cells as well as control shRNA cells, and summing the number of standardized data points that were above ( $> 0$ ) or below ( $< 0$ ) the mean for each DMAP cell population, corrected by the number of samples per population and results obtained from 1,000 random selections of DMAP genes.

### PERT deconvolution analysis

The PERT deconvolution was run on the TMM-normalized CPM data from TAZ knockdown and control samples (Qiao et al., 2012). The batch-corrected linear RMA-normalized data from the GSE24759 (DMAP) data were used as the reference profile. The vector theta from the PERT output was used to estimate the percentage of reference populations within each TAZ knockdown and control samples. The theta percentage of each biological replicate of the same populations was summed. A high theta value for one population means a high estimated presence of the profile in the TAZ knock down or control sample.

### Non-Specific Esterase Staining

Cytospin slides were prepared by centrifuging OCI-AML2 cells ( $1 \times 10^5$ ) 7–11 days after transduction (TAZ shRNA and PISD over-expression plasmids respectively) onto glass slides, which were then subsequently stained for nonspecific esterase (NSE) activity, using the staining kit from Sigma-Aldrich, as per manufacturer's instructions. The monocyte non-specific esterase inhibitor sodium fluoride was used to confirm the specificity of the reaction. Finally, glass slides were dried at room temperature, mounted in Clear Mount and scanned using the Aperio ScanScope AT2 (Leica, Wetzlar, Germany), and then analyzed by ImageJ as described below.

### NSE Staining Analysis Using ImageJ

Aperio ImageScope (Leica, Wetzlar, Germany) was used to select 5 random sections from the scanned AML cell images. ImageJ was used to quantify the intensity of NSE staining. The average of the 5 sections for each condition, from three independent experiments is presented.

### Cell Surface Phenotype of OCI-AML2

OCI-AML2 cells were co-immunostained with the viability dye 7AAD and anti-human CD11b or 7AAD and anti-human CD14. Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and analyzed with the FlowJo software (TreeStar, OR, USA).

### RNA Isolation and Quantitative Reverse Transcriptase-Real Time Polymerase Chain Reaction

Total RNA was isolated from leukemia cells using the RNeasy Plus Mini Kit (QIAGEN), and cDNA was prepared using SuperScript IV Reverse Transcriptase (ThermoFisher, MA, USA). Equal amounts of cDNA for each sample were added to a prepared master mix (Power SYBR Green PCR Master mix; Applied Biosystems, CA, USA). Quantitative real time polymerase chain (qRT-PCR) reactions were performed on an ABI Prism 7900 sequence detection system (Applied Biosystems, CA, USA). The relative abundance of a transcript was represented by the threshold cycle of amplification (CT), which is inversely correlated to the amount of target RNA/first-strand cDNA being amplified. To normalize for equal amounts of cDNA we assayed the transcript levels of 18srRNA gene. The comparative CT method was calculated as per manufacturer's instructions. Primers that were used are listed in Table S4.

### Lipid Extraction Protocols

#### Ultra-High Performance Liquid Chromatography/Mass Spectrometry (UHPLC/MS)

Frozen leukemia cells (day 13 post-transduction), or mouse bone marrow samples (12.9–19.4 weeks after doxycycline treatment) were resuspended in PBS, and then added to 2:1 chloroform:methanol (v/v) on ice. Samples were vortexed, and 400  $\mu$ L of 0.2 M sodium-phosphate buffer was added to induce layer separation. After inversion, samples were centrifuged for 5 minutes at 1734g. The organic layer, which contains the lipids, was collected. An additional 2mL of chloroform was added to the aqueous layer. Samples were re-vortexed, re-centrifuged, and the organic layer was collected and combined with the organic layer of the first extraction. The methanol/water layer was discarded. Samples were stored in chloroform at 4°C until further analysis.

#### Densitometry Analysis

Lipids from TAZ knockdown (day 8 post-transduction), PISD knockout (15 days post-transduction), PS supplemented (day 7 post supplementation), PE/LPE supplemented (day 4 post supplementation) or MMV treated (day 7 post treatment) leukemia cell lines were extracted for densitometric analysis as described previously (Folch et al., 1957). Briefly, Samples were resuspended in PBS, and mixed with 1:2 chloroform:methanol (v/v). H<sub>2</sub>O (HPLC grade) was added to increase separation. Afterward, samples were mixed then centrifuged for 6 minutes at 1700 g. The organic layer, which contains all the lipids was collected for the characterization of phospholipid distribution, using densitometric analysis.

### UHPLC/MS Characterization of MLCL and CL

UHPLC/MS analysis was performed as previously described in (Bradley et al., 2017), with modification to detect MLCL and CL. Samples were dried under N<sub>2</sub> gas and resuspended in 100 μL 65:35:5 acetonitrile:isopropanol:water (v/v/v) with 0.1% formic acid. A Dionex UltiMate 3000 UHPLC System was used (Dionex Corporation, Bannockburn, IL, USA), and was coupled to a Thermo Q-Extractive Quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific, Waltham, MA, USA). A reversed-phase, binary multistep, ultrahigh-performance liquid chromatography (UHPLC) protocol was used with a C18 Ascentis Express column with dimensions of 15cm x 2.1mm x 2.0 μm (Sigma-Aldrich®, MO, USA). The mobile phase consisted of A: 60:40 acetonitrile:water (v/v), 10mM ammonium formate, and 0.1% formic acid, and B: 90:10 isopropanol:acetonitrile (v/v), 10mM ammonium formate and 0.1% formic acid. The gradient protocol used was as follows: from 0 – 1.5 minutes it was 32% B, from 1.5 – 4 minutes 45% B, from 4 – 8 minutes 50% B, from 8 – 18 minutes 55% B, from 18 – 20 minutes 60% B, from 20 – 35 minutes 70% B, from 35 – 40 minutes 95% B, from 40 – 45 minutes 95% B, from 45 – 47 minutes B was decreased to 32%, and allowed to equilibrate until the 48 minute mark. The flow was set to 260 μL/minute, column temperature at 45°C, and tray temperature at 4°C. The injection volume was 5 μL. The mass spectrometer was operated in negative electrospray ionization mode, 35,000 resolution, with a scan range of *m/z* 200 to 2,000, spray voltage of –3.0 kV, sheath gas flow rate of 35 units, and capillary temperature of 300°C. MS/MS experiments were done under data-dependent conditions with top 5 ions and 17,500 resolution, and the normalized collision energy was 17.5. Thermo Xcalibur QualBrowser software (version 2.1; ThermoFisher Scientific, MA, USA) was used for extracting ion chromatograms, integrating peak areas, and exporting MS-MS spectra. Chromeleon Xpress (version 7.2; ThermoFisher Scientific, MA, USA) was used to monitor and control the Dionex UHPLC settings. MS/MS spectra were analyzed using the NIST MS search program (version 2.0; National Institute of Standards and Technology, MD, USA) and LipidBlast library. Extracted ion profiles were integrated for 20 cardiolipin species and 8 mono-lyso cardiolipin species using their deprotonated molecular ion *m/z* ratios ([M-H]<sup>-</sup>) within a 0.2Da window (Table S7).

### Densitometric Analysis of Phospholipids

Lipids extracted as described above, were spotted onto high-performance thin layer chromatography plates (HPTLC; 5633-5, EMD Chemicals, Darmstadt, Germany) and individual phospholipids were separated using a chloroform:methanol:acetic acid:water (100:75:7:4) solvent system (Stefanyk et al., 2010). A reference standard containing a mixture of sphingomyelin, phosphatidylcholine, PS, phosphatidylinositol, phosphatidylethanolamine, and cardiolipin was spotted alongside each plate to correctly identify the phospholipid species. After allowing the solvent to run up each plate for 45 minutes, the plates were then charred at 180°C with a 10% (w/v) copper (II) sulfate in 8% phosphoric acid solution for 15 minutes (Churchward et al., 2008). Images of the HPTLC plates were captured using a CCD camera on a Fluorchem 5500 imaging station (Alpha Innotech, CA, USA) under reflective white light, and then quantified as described in densitometric phospholipid analysis section below.

### Densitometric Phospholipid Analysis

Densitometry analyses were then performed using Image Studio™ (LI-COR, NB, USA) and the percent distribution of each phospholipid specie was calculated by dividing the densitometric value for the individual phospholipid specie by the sum of the densitometric values for all phospholipid species combined.

### Quantification of Extracellular PS

OCI-AML2 cells were transduced with shRNA in lentiviral vectors targeting TAZ or control sequences. Seven days after transduction, cells were harvested, and cell death was measured by flow cytometry with annexin V fluorescein isothiocyanate (FITC) and propidium iodide (PI) (Biovision Research Products, CA, USA) staining according to the manufacturer's instructions. Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and frequency of annexin V positive cells were quantified by with the FlowJo software (TreeStar, OR, USA)

### PS Quantification by Confocal Microscopy

Cytospin slides were prepared by centrifuging 10,000 TAZ knockdown 8227 (day 11 post-transduction) or primary AML (day 7 post-transduction) cells onto glass slides, which were then fixed in 4% paraformaldehyde for 5 minutes, permeabilized (0.2% saponin) for 20 minutes, and then stained with annexin V Alexa-647 (1:15) for 1 hour, and DAPI (1:500) for 2 minutes, and then mounted with anti-fade solution. Finally, images were acquired using the Olympus FV1000 (Tokoyo, Japan) confocal microscope, and the amount of PS was quantified as described below.

### PS Quantification Using ImageJ

Olympus FV1000 was used to select 10-13 random sections from acquired AML cell images. ImageJ was used to quantify the number of DAPI+ cells, and intensity of PS staining. Then, the average PS intensity per cell of each image acquired was quantified by ImageJ using the formula:

$$\text{Integrated intensity of PS} \div \# \text{DAPI+ Cells}$$

The average of the 10-13 sections for each condition is presented.

### Sensitivity to Extrinsic Apoptosis

OCI-AML2 cells transduced with shRNA in lentiviral vectors targeting TAZ or control sequences were then co-treated with 2.5  $\mu\text{g}/\text{mL}$  of cyclohexamide and increasing concentrations of TRAIL for 16 hours, 13 days after transduction. Cells were stained with annexin V and PI staining (BD Biosciences, FL, USA) according to the manufacturer's instructions. Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and frequency of annexin V, PI negative cells were quantified with the FlowJo software (TreeStar, OR, USA)

### Seahorse

Oxygen consumption rate (OCR), and extracellular acidification rate (ECAR) were measured in AML cells after TAZ or PISD knock-down using the Seahorse XF-96 analyzer (Seahorse Bioscience, MA, USA). OCR was measured as a marker of electron transport chain activity. Six days (TAZ knockdown) or 8 days (PISD knockout) after transduction cells were resuspended in unbuffered medium and seeded at  $1 \times 10^5$  cells/well in Cell-Tak coated (0.15  $\mu\text{g}/\text{well}$ ) XF96 plates. Cells were equilibrated in the unbuffered  $\alpha$ -MEM medium (supplemented with 2% FCS) or XF Assay medium (supplemented with 4.5 g/l (25mM) glucose + 1mM pyruvate) for 45 minutes at 37°C in a CO<sub>2</sub>-free incubator before being transferred to the XF96 analyzer. Spare reserve capacity of the mitochondrial respiratory chain was measured by treating cells with oligomycin, and FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) in succession.

### Cellular Reactive Oxygen Species

Four days after transduction with TAZ or control shRNA sequences cells were stained with Carboxy-H<sub>2</sub>DCFDA in PBS buffer at 37°C for 30 minutes, and resuspended in PBS with the viability dye PI to assess the reactive oxygen species produced by viable cells. Data was acquired by LSRFortessaX20 (BD Biosciences, FL, USA), and MFI of Carboxy-H<sub>2</sub>DCFDA in PI negative cells were analyzed using FloJo (TreeStar, OR, USA).

### Mitochondrial Mass

Eight days after transduction with TAZ or control shRNA sequences mitochondrial mass was characterized by quantifying the mtDNA to nuclear DNA ratio. mtDNA and nuclear DNA was extracted using the DNeasy Blood and Tissue kit (QIAGEN, MD, USA) from AML cell lines transduced with lentiviral vectors with shRNA targeting TAZ, or control sequences. The relative amount of mtDNA to nuclear DNA was measured using qRT-PCR, using primer pairs for mitochondrial ND1, and nuclear HGB outlined in [Table S4](#).

### Live Imaging

The mitochondrial morphology of cells transduced with shRNA in lentiviral vectors targeting TAZ or control sequences, was assessed in live cells by labeling the mitochondria with 1  $\mu\text{M}$  MitoTracker and Red CMXRos (ThermoFisher Scientific, MA, USA) for 30 minutes at 37°C, 7 days after transduction. Cells were washed twice with complete media and transferred to a poly-L-lysine (Sigma-Aldrich®, MO, USA) coated imaging plate. Images were acquired on spinning disc confocal microscope VisiScope CSU-W1 Olympus IX83 (Tokyo, Japan). Mitochondria shape was characterized by quantifying mitochondrial aspect ratio as described below.

### Aspect Ratio

For mitochondrial shape assessment an aspect ratio of each mitochondrion was measured, confocal z-stacks were collected and projected as a z-project in ImageJ (NIH, Bethesda, MD). The population median, quartiles, minimum, and maximum of fields (40-60 cells) are expressed as a boxplot.

### Electron Microscopy

The mitochondrial morphology of cells transduced with shRNA in lentiviral vectors targeting TAZ or control sequences, was assessed by transmission electron microscopy (TEM). To perform TEM, cells were harvested at day 8 post-transduction, and fixed with a modified Graham-Karnovsky's fixative-4% paraformaldehyde plus 1% glutaraldehyde in 0.1 M phosphate buffer pH 7.2 (PB)-for 30 minutes at room temperature, and 4°C overnight. Cells were then washed with phosphate buffer (PB, NaH<sub>2</sub>PO<sub>4</sub>. H<sub>2</sub>O + Na<sub>2</sub>H<sub>2</sub>PO<sub>4</sub>) 3 times for 15 minutes. Next, cells were post-fixed with 1% osmium tetroxide buffered with PB for 1 hour and washed again using PB twice for 20 minutes, dehydrated with an ethanol series then infiltrated with propylene oxide. The samples were then resin embedded with Epon, which was polymerized at 40°C for 48 hours. Solid epoxy blocks were sectioned on a Reichert Ultracut E microtome to 90 nm thickness, collected on 300 mesh copper grids and counterstained with uranyl acetate and lead citrate. A Hitachi H7000 (Hitachi, Tokyo, Japan) transmission electron microscope with a beam current of 25  $\mu\text{m}$ , was used to view the sections. Images of the sections were acquired by the Advanced Microscopy Techniques (AMT)-CCD camera (AMT, MA, USA). A composite of representative images acquired are shown in [Figure S4](#).

### Lipid-Protein Overlay Assay

Binding of PISD to lipid strips (Echelon Biosciences) was performed as per manufacturer's instructions. Briefly, strips were blocked in 3% fatty acid-free BSA in TBS (25 mM Tris, 150 mM NaCl pH7.2) followed by incubation with 1  $\mu\text{g}/\text{mL}$  of PISD recombinant protein in

1% fatty acid-free BSA in TBS for 16 hours at 4°C. Strips were washed extensively in TBST (0.05% Tween-20 in TBS) buffer to remove unbound proteins, and incubated with PISD antibody for 16 hours at 4°C. PISD protein bound to lipid strips were detected by immunoblotting.

### Lipid Supplementation and Growth Analysis

All lipids were purchased from Avanti Polar lipids, lysophosphatidylethanolamine (LPE), phosphatidylethanolamine (PE), PS. A stock solution of LPE (18mM) and PE (25mM) were made by dissolving lipid powder in 65 chloroform: 35 methanol: 8 water (v:v:v), whereas a 25mM stock solution of PS was made by dissolving PS powder in 70% methanol: 20% TWIN-80: 10% Propylene Glycol (PEG) (v:v:v). After lipid supplementation, equal numbers of cells were plated for growth assay, and counted by trypan blue exclusion staining for a period of 8-14 days.

### MMV Treatment and Growth Analysis

Cell lines or primary samples were seeded at  $1 \times 10^5$  cells/mL in 20 mL of medium in T75 flasks. Cells were then treated with increasing concentrations of MMV007285 or DMSO control. Fresh MMV or vehicle control was added every 3 days during the incubation period. After MMV treatment, equal numbers of cells were plated for growth assay, and counted by trypan blue exclusion staining for a period of 14 days

### 8227 Flow Cytometry

8227 cells were co-immunostained with the viability dye Aqua Dead (ThermoFisher Science, MA, USA), anti-human antibodies recognizing CD34, CD38, Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and frequency of viable 34+,38- cells were analyzed with the FlowJo software (TreeStar, OR, USA).

### PS Quantification by Flow Cytometry

Five days after MMV treatment primary AML cells were fixed in 4% paraformaldehyde for 5 minutes, permeabilized (0.2% saponin) for 20 minutes, and then stained with Annexin V FITC (1:25) for 1 hour. Flow cytometry data were acquired using a LSRFORTESSA X20 (BD Biosciences, FL, USA) flow cytometer and annexin V MFI was analyzed with the FlowJo software (TreeStar, OR, USA).

### MMV and CL075 Synergism Studies

OCI-AML2 leukemia cells were seeded in 96 well plates, and then treated with increasing concentrations of CL075 with and without increasing concentrations of MMV007285. Cells were incubated at 37°C with 5% CO<sub>2</sub> for 72 hours. Cell growth and viability was determined using the MTS assay (Promega), as per manufacturer's instructions. For each combination excess over Bliss additivity (EOBA) values were calculated as previously described (Boris et al., 2003).

### Animal Studies

#### Hematopoiesis in WT and Taz-KD mice

In order to understand the role of TAZ in normal hematopoiesis under basal conditions, adult (7.6-14.3) week IDOX-TAZ-KD mice were treated with doxycycline for 12.9-19.4 weeks, and then sacrificed.

To understand the role of TAZ in hematopoietic stress, doxycycline treated IDOX-TAZ-KD mice were injected intraperitoneally (IP) with 200mg/kg of 5-FU (Sigma-Aldrich®, MO, USA), dissolved in phosphate-buffered saline (GIBCO, MA, USA). Peripheral blood was collected at 0, 3, 7, 10, 15, and 23 days after 5-FU injection from the tail vein into EDTA-containing tubes. White blood cell, neutrophil, lymphocyte, red blood cell, and platelet counts were enumerated using the HEMAVET 950FS (Drew Scientific Inc, FL, USA). All mice were sacrificed 15 or 23 days after 5-FU treatment.

At the time of sacrifice, blood was isolated by cardiac puncture for complete blood counts, and hematopoietic cells were flushed from the femur and tibiae of WT and iDOX-TAZ-KD mice, using DMEM + 2% FCS. Red cell were lysed, and the remaining cells were passed through a 100µm strainer. Bone marrow samples were depleted of mature myeloid and lymphoid lineages (Lin<sup>-</sup>) using magnetic bead separation with biotin-conjugated antibodies CD5, CD45R (B220), CD11b, Anti-Gr-1 (Ly-6G/C), 7-4 and Ter-119 (Miltenyi Biotec, mouse lineage depletion kit).

Lin<sup>-</sup> cells were co-immunostained with anti-mouse antibodies recognizing Sca1, CKIT, CD48, CD150, CD34, and FCyR, and the viability dye 7AAD. Flow cytometry data were acquired using a FACSCanto II (BD Biosciences) flow cytometer and analyzed with the FlowJo software (TreeStar, OR, USA).

#### TEX and 8227 Engraftment

Equal numbers of TEX or 8227 cells ( $1-2 \times 10^6$ ) transduced with shRNA sequences in lentiviral vectors targeting TAZ or control sequences or treated with vehicle control or PS, were injected into the right femur of sublethally irradiated NOD-SCID-GF mice with human IL-3, GM-CSF, and Steel factor (SF) (Nicolini et al., 2004). Five weeks after injection, mice were sacrificed, and the percentage of human CD45+ was enumerated in TEX and PS supplemented 8227 cells by flow cytometry. Whereas in 8227 cells transduced with TAZ shRNA, engraftment of cells into the bone marrow was assessed by measuring GFP+ CD45+ cells by flow cytometry, and then calculating relative human cell engraftment as described in the calculation of engraftment potential section.

### Stability and Pharmacokinetics of MMV007285

The concentration of intact MMV007285 in blood plasma was measured using Waters

Xevo Quadruple Time-of-flight (Q-ToF) hybrid mass spectrometer (MS) system coupled with

ACQUITY ultra-performance liquid chromatography (UPLC) (Waters Limited, Mississauga, Canada). Chromatographic separations were carried out on an ACQUITY UPLC BEH C18 (2.1 X 50 mm, 1.7  $\mu$ m) column (Waters Limited, ON, Canada). The mobile phase was 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). Compound concentrations were measured relative to a freshly prepared calibration curve.

### Subcutaneous AML Xenografts

To understand the role of TAZ in AML differentiation and PISD in AML growth *in vivo*, OCI-AML2 or CAS9-OCI-AML2 cells were first transduced with shRNA targeting TAZ/control sequences, or sgRNA targeting PISD/control sequences respectively.  $1 \times 10^6$  transduced cells were then injected subcutaneously into the flanks of male SCID mice (Ontario Cancer Institute). Differentiation after TAZ knock down was evaluated by measuring differentiation markers in sub-cutaneous tumors 8 days after injection, whereas role of PISD in tumor growth was characterized by measuring tumor volume every 2-3 days.

The *in vivo* anti-tumor activity and toxicity of MMV007285 was also assessed by injecting OCI-AML2 human leukemia cells ( $1 \times 10^6$ ) subcutaneously into the flanks of male SCID mice (Ontario Cancer Institute). When the tumors were palpable, mice were treated with MMV007285 or vehicle control (5% DMSO, 47.5% PEG400, 10% Tween80, 37.5% H<sub>2</sub>O) by oral gavage (300 mg/kg twice daily for 5 of 7 days) for 10 days (n = 10/group). Tumor volume was measured every 2-3 days. Nineteen after injection mice body weight was measured, afterward mice were sacrificed, peripheral blood was collected then alkaline phosphatase (ALP), aspartate transaminase (AST), bilirubin (Bili), creatine kinase (CK), creatinine (Cr) levels were measured by Idexx Laboratories (Ontario, Canada).

### Primary AML Engraftment Models

The role of TAZ in leukemia stem cells *in vivo* was characterized by transducing primary AML patient samples with TAZ shRNA or control shRNA containing lenti-viral vectors. NOD-SCID mice were conditioned with 208 rad of irradiation from a 137 rad source, and a 200  $\mu$ g of anti-mouse CD122 48 hours before transplantation. Forty-eight hours after transduction  $3 \times 10^5$ - $1 \times 10^6$  cells were injected into the right femurs of conditioned NOD-SCID mice, 6-8 weeks after, mice were sacrificed, cells were flushed from the femora, and then stained with CD33. The percentage of human GFP+, CD33+ cells in the bone marrow was determined by flow cytometry. The engraftment of transduced human AML cells into the bone marrow was assessed by enumerating relative human cell engraftment as described in the calculation of engraftment potential section.

To assess effect of MMV on leukemia initiating cells *in vivo*, a frozen aliquot of Primary AML patient samples were thawed, and pre-treated with MMV007285 or DMSO for 48 hours, in IMDM supplemented with 20% FCS, 100 units/mL penicillin and 100  $\mu$ g/mL of streptomycin before transplantation. The day before transplantation, NOD-SCID mice conditioned as described above. Then,  $2 \times 10^6$  viable treated cells were injected into the right femurs of 10 week-old female NOD-SCID mice. Six weeks after, mice were sacrificed, cells were flushed from the femora. Engraftment of human AML cells into the bone marrow was assessed by enumerating the percentage of human hematopoietic myeloid cells with the cell surface signature of CD45+CD33+CD19- by flow cytometry using the BD Biosciences FACSCanto. Data were analyzed with FlowJo version 7.7.1 (TreeStar, OR, USA).

Whereas, to characterize the effect of MMV007285 on AML patient stem cell propagation properties *in vivo*, a frozen aliquot of Primary AML patient samples were thawed, counted and re-suspended in PBS, and  $2 \times 10^6$  viable trypan blue negative cells were injected into the right femurs of NOD-SCID mice, conditioned as described above. Eleven days after transplantation mice were treated with MMV007285 (150mg/kg) by oral gavage or vehicle control (n = 9 mice vehicle control group, n = 10 mice MMV007285 group) once daily for 5 of 7 days for 5 weeks. Mice body weight was measured at the end of the experiment (41 days after AML patient sample transplantation). Afterward mice were sacrificed, and AML cell engraftment bone marrow was measured as described above. Also, at sacrifice, peripheral blood was collected and then alkaline phosphatase, aspartate transaminase, bilirubin, creatine kinase, creatinine levels were measured by Idexx Laboratories (Ontario, Canada).

The effects of MMV007285 on leukemia stem cell disease initiating properties were further characterized by injecting equal numbers of human leukemia cells isolated from the bone marrow of MMV007285 or DMSO treated mice, into secondary NOD-SCID mice that were conditioned as described above, but not treated with MMV007285. Six week later, human leukemia cell engraftment in the bone marrow was measured by flow cytometric analysis as described above.

### Calculation of Engraftment Potential

Relative engraftment was measured as described in Pei et al. (2018). Using flow cytometry, we first measured % of GFP+ cells within the 7AAD- gate to determine the % of shRNA-expressing cells injected (%GFP-injected). After engraftment, we also measured % of viable GFP+, human CD33+ (primary AML samples) or % of GFP+, human CD45+ (8227) cells to determine the % of shRNA-expressing cells engrafted (%GFP-engrafted). For each experimental group, we first calculated engraftment value TAZ shRNA or control shRNA using the following formula: TAZ shRNA or control shRNA = %GFP-engrafted  $\div$  %GFP-injected for each mouse. This calculation yielded an array of engraftment values for both control shRNA and TAZ shRNA groups. To calculate the final relative engraftment potential score, each engraftment value was normalized to the mean engraftment of the control shRNA group. These scores were plotted to compare the relative engraftment potential between control and TAZ shRNA.

## QUANTIFICATION AND STATISTICAL ANALYSIS

In all figures, n represents technical replicates and N represents independent biological replicates. Blinded analysis was implemented into the experimental design when possible. Data are mean  $\pm$  standard error of the mean (SEM) or mean  $\pm$  standard deviation (SD). Prism Graph Pad 6.0 was used to perform statistical analysis and data plotting unless otherwise specified in figure legends. A Two-Way ANOVA followed by a post hoc Dunnett's test was used to compare two or more variables between three groups, and a Two-Way ANOVA followed by a post hoc Bonferroni test was used to compare two or more variables between two groups. A One-Way ANOVA followed by a post hoc Dunnett's test was used to compare one variable between three groups unless otherwise stated. Finally, an unpaired Student's t test was used to compare the mean between two groups. The level of significance is indicated as follows: \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ . A detailed description of the experimental setup and statistical analysis is in the figure legends.

## DATA AVAILABILITY


AML gene expression after TAZ knock down has been deposited in the Gene Expression Omnibus database under the accession code GEO: GSE107045.

## Supplemental Information

### **The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids**

**Ayesh K. Seneviratne, Mingjing Xu, Juan J. Aristizabal Henao, Val A. Fajardo, Zhenyue Hao, Veronique Voisin, G. Wei Xu, Rose Hurren, S. Kim, Neil MacLean, Xiaoming Wang, Marcela Gronda, Danny Jeyaraju, Yulia Jitkova, Troy Ketela, Michael Mullokandov, David Sharon, Geethu Thomas, Raphaël Chouinard-Watkins, James R. Hawley, Caitlin Schafer, Helen Loo Yau, Zaza Khuchua, Ahmed Aman, Rima Al-awar, Atan Gross, Steven M. Claypool, Richard Bazinet, Mathieu Lupien, Steven Chan, Daniel D. De Carvalho, Mark D. Minden, Gary D. Bader, Ken D. Stark, Paul LeBlanc, and Aaron D. Schimmer**

**Figure S1. Related to Figure 1**




**Figure S1. Related to Figure 1. Knockdown of Tafazzin reduces the growth of leukemia cells lines.**

(A-B) Proliferation and TAZ protein expression of K562 (A) and U-937 (B) cells after TAZ knockdown. The relative AUC of viable cell counts over 12 days are shown (Control shRNA = 100%). Data are relative mean  $\pm$  SEM (N = 4, K562; N = 3, U-937, Control shRNA=100%). \*\*\*\*p<0.0001 using one-way ANOVA and Dunett's post hoc test.

(C) Cell viability of OCI-AML2 cells after TAZ knockdown. Data are mean  $\pm$  SEM of three independent experiments.

(D-F) Cell cycle status (D) (G0/G1)-S ratio (E), or (G0/G1)-G2 ratio (F), after TAZ knockdown. Data are mean  $\pm$  SEM of three independent experiments. \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001 by Two-Way ANOVA (cell cycle status) or one-way ANOVA (all other graphs) and Dunett's post hoc test.

Figure S2. Related to Figure 2



**Figure S2. Related to Figure 2. Knockdown of Tafazzin reduces AML Stemness and increases the expression of genes associated with granulocytic/neutrophilic populations.**

(A) Unsupervised hierarchical clustering of gene expression data from the TCGA AML cohort (n = 179). Values above each branching represent percent approximate unbiased p values calculated by 1000 bootstrap resampling using the R package pvclust. The most differentially expressed genes (top 500) genes between the two TCGA clusters were compared with Gene Expression Omnibus dataset GSE24759 (DMAP) populations. Each bar is a measure of the expression of these genes in each DMAP population compared to the mean of all DMAP populations (mean is equal to 0). Numbers beside bars indicate the percentage of time for which the observed value was better represented in a specific DMAP population than random values (equal number of randomly selected genes based on 1,000 trials).

(B) Gene set enrichment analysis (GSEA) measure of the TCGA stem-like or myeloid-like genes in the TAZ shRNA or control shRNA gene signatures. The normalized enrichment scores (NES), and false discovery rates (FDRs) are indicated in each plot.

(C) The most differentially expressed genes (top 500) between TAZ shRNA2 and control samples were compared with Gene Expression Omnibus dataset GSE24759 (DMAP) populations. Each bar is a measure of the expression of these genes in each DMAP population compared to the mean of all populations (mean is equal to 0). Numbers beside bars indicate the percentage of time for which the observed value was better represented in a specific DMAP than random values (equal number of randomly selected genes based on 1,000 trials).


(D) Proportions of control shRNA or TAZ-KD samples that possess gene expression profiles of undifferentiated HSC or mature myeloid cells, as determined by the perturbation (PERT) deconvolution analysis using gene expression data from normal hematopoietic subsets.

(E-F) CD11b (E) and CD14 (F) expression in OCI-AML2 cells after TAZ knockdown. Data are relative mean fluorescent intensity (MFI)  $\pm$  SD (n = 3, Control shRNA = 1.0).

(G) Lysozyme (LYZ) levels in OCI-AML2 cells transplanted into SCID mice after TAZ knockdown. Data represent relative mean  $\pm$  SD (n = 3 mice/group, Control shRNA = 1.0). \*p $\leq$ 0.5 by Student's t-test.

(H) Clonogenic growth of TEX cells after TAZ knockdown upon serial replating. Data are relative mean  $\pm$  SEM of three independent experiments (Control shRNA = 100%). \*\*\*\*p $\leq$ 0.0001 by Student's t-test.

Figure S3. Related to Figure 3



**Figure S3. Related to Figure 3. Mature blood counts and progenitor cell function of WT and *Taz*-KD mice after the induction of hematopoietic stress.**


(A) Schematic outlining the induction of hematopoietic stress by 5-FU.

WT and *Taz*-KD mice were treated with 200mg/kg of 5-FU i.p. Arrows indicate the days that peripheral blood of WT and TAZ-KD mice were collected.

(B-F) White blood cells (B), neutrophils (C), lymphocytes (D), erythrocytes (E), and platelets (F) levels in the mice in A. Data are relative mean  $\pm$  SEM of 2 independent mouse groups ( $n = 7$  WT mice, and  $n = 6$  *Taz*-KD mice, D0 = 100%).

(G) Clonogenic growth of hematopoietic cells in 5-FU treated *Taz*-KD mice upon serial replating. Data represent relative mean  $\pm$  SEM of 2 independent mouse groups ( $n = 7$  WT mice, and  $n = 5$  *Taz*-KD mice, WT mice CFU-GM=100%).

Figure S4. Related to Figure 4



**Figure S4 Related to figure 4. Knockdown of Tafazzin in OCI-AML2 cells reduces TAZ activity but does not affect mitochondrial structure or function.**

(A-H) The relative abundance of MLCL given chain lengths (A), CL chain lengths (B), and the distribution of double bonds per acyl chain length (C-H). Data are mean  $\pm$  SEM of three independent experiments. \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$  by one-way ANOVA (64:3 graph), Two-Way ANOVA (all other graphs), and a post hoc Dunnett's test.

(I) Cell viability of OCI-AML2 cell after TAZ knockdown when treated with cyclohexamide, and TRAIL for 16 hours. Data are relative mean  $\pm$  SD of a representative experiment from 3 independent experiments (0ng/mL TRAIL = 100%).

(J-K) Basal OCR (J) and reserve OCR (K) in OCI-AML2 cells after TAZ knockdown. Data are relative mean  $\pm$  SD of a representative experiment from 3 independent experiments (Control shRNA=100%). \*\*\*\* $p \leq 0.0001$  by one-way ANOVA, and a Dunnett's post hoc test.

(L) Cellular ROS of OCI-AML2 cells after TAZ knockdown. Data are mean  $\pm$  SD of a representative experiment from 3 independent experiments (Control shRNA = 100%)


(M) Mitochondrial mass of OCI-AML2 cell after TAZ knockdown by the measurement of ND1 levels. Data represent mean  $\pm$  SD (n=3, Control shRNA = 1.0).

(N) Mitochondrial morphology of cells from D. Composite of representative images are shown. Scale bar = 2 $\mu$ m or 500nm

(O) Boxplot of mitochondrial aspect ratio in OCI-AML2 cells after TAZ knockdown.

(P) ECAR of cells from (A). Data are relative mean  $\pm$  SD of a representative experiment from 3 independent experiments (Control shRNA=100%). \*\*\*\*p $\leq$ 0.0001 by one-way ANOVA, and a Dunnett's post hoc test.

**Figure S5. Related to Figure 4**



**Figure S5. Related to Figure 4 Phosphatidylserine accumulation, as well as PISD decrease is functionally important in AML growth and viability after TAZ-KD.**

(A) QRT-PCR of TAZ in primary AML cells after TAZ knockdown. Data are mean  $\pm$  SEM of two independent experiments. \*\*\*\* $p$  $\leq$ 0.0001 Student's t-test.

(B-C) Intracellular phosphatidylserine levels of 8227 (B), and primary AML cells (C). Data are mean integrated PS staining intensity/DAPI+ cells  $\pm$  SD (n = 8-12 images). \* $p$  $\leq$ 0.5, \*\*\* $p$  $\leq$ 0.001 by Student's t-test.

(D) Phosphatidylethanolamine (PE) levels in OCI-AML2 cells after PE or lyso-phosphatidylethanolamine (LPE) supplementation. Data are mean  $\pm$  SD (n = 3, Control = 1.0). \* $p$  $\leq$ 0.05 by one-way ANOVA, and Dunnett's post hoc test.

(E-F) Proliferation TAZ knockdown OCI-AML cells after PE (E) or LPE (F) supplementation. The relative area under the curve (AUC) of viable cell counts 12 days after transduction is shown (Control shRNA = 100%). Data represents mean  $\pm$  SD of representative experiment from 3 independent experiments. \* $p$  $\leq$ 0.05, \*\* $p$  $\leq$ 0.01, \*\*\*\* $p$  $\leq$ 0.001 by one-way ANOVA and Tukey's post hoc test.

(G) Protein and mRNA levels of the PE synthesizing enzyme phosphatidylserine decarboxylase (PISD) in OCI-AML2 cells after TAZ knockdown. An immunoblot from three independent experiments is shown. QRT-PCR data are mean  $\pm$  SD (n = 3, Control shRNA=1.0).


(H) Protein levels of the PS synthesizing enzymes PS synthase 1 (PSS1) and PS synthase 2 (PSS2) in OCI-AML2 cells after TAZ knockdown. An immunoblot from four independent experiments is shown.

(I) Clonogenic growth of Cas9-OCI-AML2 after PISD knockout upon serial replating. Data are relative mean  $\pm$  SEM of 2 independent experiments. (Control sgRNA=100%). \*\* $p \leq 0.01$  \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.001$  by Student's t-test.

(J-K) Basal OCR (J) and reserve OCR (K) in of Cas9-OCI-AML2 after PISD knockout. Data are relative mean  $\pm$  SD of a representative experiment from 2 independent experiments (Control shRNA = 1.0).

(L-M) PISD mRNA expression (L) and NSE staining (M) of TAZ knockdown OCI-AML2 cells after PISD over expression. In (L) Data are mean  $\pm$  SD (n = 3). \*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$  by one-way ANOVA and Tukey's post hoc test. In (M) data represent relative mean  $\pm$  SD of a representative experiment from 2 independent experiments (Control shRNA = 100%). \*\*\*\* $p \leq 0.0001$  by one-way ANOVA and Tukey's post hoc test.

**Figure S6. Related to Figure 6**



**Figure S6. Related to Figure 6. TLR8 agonist CL075 reduces stemness in OCI-AML2 cells, and synergizes with MMV007285.**

(A) Proliferation of OCI-AML2 cells after treatment with increasing concentrations of CL075 or vehicle controls. The relative AUC of viable cell counts over 14 days are shown (Control shRNA = 100%). Data are the relative mean  $\pm$  SEM (0μM = 100%) of two independent experiments. \*\*\*p<0.001, \*\*\*\*p<0.0001 by one-way ANOVA and Dunnett's post hoc test.

(B-C) CD11b expression in OCI-AML2 cells seven (B) or fourteen (C) days after treatment with CL075. Data are relative mean fluorescent intensity (MFI)  $\pm$  SEM of 2-3 independent experiments (0μM = 1.0). \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001 by one-way ANOVA and Dunnett's post hoc test.

(D) QRT-PCR of toll-like receptor 8 (*TLR8*) of OCI-AML2 cells were treated with 6 or 24 hours after treatment with MMV007285 alone, CL075 alone or MMV007285 + CL075. Data represent mean  $\pm$  SD (n = 3, Control, 0μM MMV + 0μg/mL CL075 = 1.0). \*\*\*\*p<0.0001 by Two-Way ANOVA and Tukey's post hoc test.

(E) Excess over bliss additivism score of the combination of MMV007285 and CL075 on cell viability. A representative experiment of two independent experiments is shown.

Figure S7. Related to Figure 7




Figure S7. Related to figure 7 increased PS reduces leukemia burden in xenograft models of human AML.

(A-E) Raw data of the engraftment experiment performed in 8227 (A), and AML patient sample cells (B-E) evaluating the impact of TAZ loss on engraftment potential. The y-axis (%GFP+ cells in viable cells) indicates % of shRNA-positive cells in injected or engrafted human cells. In the engrafted group each dot represents an individual mouse, lines represent mean. This figure is related to the normalized relative engraftment potential data presented in Figure 7A-E.

(F) Plasma concentration of intact MMV007285 in SCID mice treated with a single dose of MMV007285 (100mg/kg) dissolved in 5% DMSO, 47.5% PEG400, and 47.5% H<sub>2</sub>O containing 10% Tween80, via oral gavage. Data represent mean ± SD (n = 3 mice).

(G) Mice body weights, biochemical markers of liver (alkaline phosphatase, aspartate transaminase, bilirubin), muscle (creatinine kinase), and renal (creatinine) toxicity of SCID mice xenografted with OCI-AML2 cells MMV007285 or vehicle control. Data represent mean ± SD (n = 10 mice per group for body weights, and n = 4 mice/group for biochemical markers).

(H) Mice body weight, biochemical markers of liver (alkaline phosphatase, aspartate transaminase, bilirubin), muscle (creatinine kinase), and renal (creatinine) toxicity of NOD/SCID mice injected with primary AML patient samples treated with MMV007285 or vehicle control. Data represent mean ± SD (n = 9 mice vehicle control group, n=10 mice MMV group). \*\*p<0.01, as determined by Student's t-test

## Supplementary Tables

Condition	Mouse Type	Mouse ID	Cell Number (1 x 10 <sup>6</sup> )	
Basal Hematopoiesis	WT	100	58.2	
		114	75.9	
		115	51.9	
		121	39.1	
		124	41.8	
		130	50.8	
		131	44.5	
		132	36.7	
		133	31.6	
		134	31.9	
		Average	46.2	
		Standard Deviation	12.9	
		TAZ-KD	104	50.0
			105	49.2
			108	62.0
			113	57.9
			116	66.0
			122	52.9
			123	53.2
			136	28.3
	Average		52.4	
	Standard Deviation		11.4	
Hematopoietic Stress (200mg/kg 5-FU)		154	7.2	
		156	10.0	
		195	22.0	
		197	35.0	
		198	33.0	
		Average	21.4	
		Standard Deviation	12.8	
		TAZ-KD	152	23.0
			153	12.5
			155	7.1
			159	8.5
			192	19.0
			193	45.0
			Average	19.2
	Standard Deviation	6.82		

Table S2. Mouse Bone Marrow Mononuclear Cell Count, Related to Figures 3 and S3.

Cell line	Species	Tissue	Sex	Age
OCI-AML2	<i>Homo sapiens</i> , human	Peripheral Blood	Male	65
TEX	<i>Homo sapiens</i> , human	Cord Blood	n/a	n/a
U-937	<i>Homo sapiens</i> , human	Pleural Effusion	Male	37
K562	<i>Homo sapiens</i> , human	Bone Marrow	Female	53
8227	<i>Homo sapiens</i> , humans	n/a	n/a	n/a
293T	<i>Homo sapiens</i> , humans	Fetal Kidney	n/a	n/a

Table S3. Cell Lines, Related to STAR Methods.

Gene	Strand	Sequence	Reference
<b>TAZ (Human AML)</b>	Forward	5'-TTGCTGCCTTCTGGATTCTT-3'	This study
	Reverse	5'-CCCTGCCTAAGCTTCTTCCT-3'	
<b>PISD (Human AML)</b>	Forward	5'-CAACCTCAGCGAGTTCTTCC-3'	This Study
	Reverse	5'-CGACTCCAGGGAGTAGGTGA-3'	
<b>18srRNA (housekeeping, human)</b>	Forward	5'-AGGAATTGACGGAAGGGCAC-3'	Lab Stock
	Reverse	5'-GGACATCTAAGGGCATCACA-3'	
<b>LYZ</b>	Forward	5'-GCCAAATGGGAGAGTGGTTA-3'	This Study
	Reverse	5'-ATCACGGACAACCCTCTTTG-3'	
<b>iDOX-Taz-shRNA Transgene</b>	Forward	5'-CCATGGAATTCGAACGCTGACGTC-3'	Khuchua Lab
	Reverse	5'-TATGGGCTATGAACTAATGACCC-3'	
<b>ND1</b>	Forward	5'-AACATACCCATGGCCAACCT-3'	Lab Stock
	Reverse	5'-AGCGAAGGGTTGTAGTAGCCC-3'	
<b>HGB</b>	Forward	5'-GAAGAGCCAAGGACAGGTAC-3'	Lab Stock
	Reverse	5'-CAACTTCATCCACGTTACC-3'	
<b>TLR4</b>	Forward	5'-TGAGCAGTCGTGCTGGTATC-3'	This Study
	Reverse	5'-CAGGGCTTTTCTGAGTCGTC-3'	
<b>TLR8</b>	Forward	5'-CAGAGCATCAACCAAAGCAA-3'	This Study
	Reverse	5'-CTGTAACACTGGCTCCAGCA-3'	
<b>IL6</b>	Forward	5'-GGAGACTTGCCTGGTAAAA-3'	(Murakami et al., 2013)
	Reverse	5'-GTCAGGGGTGGTTATTGCAT-3'	
<b>IFN<math>\beta</math></b>	Forward	5'-CAACTTGCTTGGATTCTACAAAG-3'	This Study
	Reverse	5'-TATTC AAGCCTCCCAATTCAATTG-3'	

Table S4. PCR Primers, Related to STAR Methods.

Patient ID	Disease	Age at Collection	Sex	Cytogenetics	Molecular	Status of Sample
110839	AML, undifferentiated	86	M	58-59,CYY,-2,-3,-4,-5,-6,-7,-9,-12,-13,add(15)(q24)x2,-16,-16,-17,-17,-19,-20,+22,+r,+2-7mar[cp14]	Not Done	Diagnostic
0676	AML, undifferentiated	79	M	46-48,XY,+6,del(13)(q12q22),+del(13)(q12q22)[cp9]/46,XY[11]	Not Done	Diagnostic
120021	AML, with maturation	88	F	46,XX,1~5dmin[13]/46,XX[7]	Not Done	Diagnostic
160556	AML with myelodysplasia-related features	57		46,XY,t(3;5)(q21;q35)[10]	Not Done	Diagnostic
162111	AML with mutated NPM1	18	M	45,X,-Y[9]/46,XY[11]	NPM1+, FLT3-ITD-	Diagnostic
100565	AML	65	M	46,XY,t(6;11)(q27;q23)[19]/46,XY[1].nuc ish(MLLx2)(5'MLL sep 3'MLLx1)[148/200]	Not Done	Diagnostic
120541	AML with mutated NPM1	51	F	46,XX[20]	NPM1+, FLT3-ITD+	Diagnostic
120287	AML with mutated NPM1	77	M	46,XY[20]	NPM1+, FLT3-ITD+	Diagnostic
120860	AML with t(9;11)(p22;q23); MLLT-MLL	31	F	46,XX,t(9;11)(p22;q23)[10]	Not Done	Diagnostic

Table S5. Clinical Characteristics of Primary AML Patient Samples, Related to STAR Methods.

Gene shRNA name	Reference	Sequence
Control sgRNA	N/A	5'-CCCGAATCTCTATCGTGCGG-3'
TAZ sgRNA1	Gene ID: 6901	5'-TACGAGCTCATCGAGAAGCG-3'
TAZ sgRNA2	Gene ID: 6901	5'-GCTCATCGAGAAGCGAGGCC-3'
PISD sgRNA	Gene ID: 23761	5'-AGCTGCCACACTGGCTGCGC-3'
Control shRNA (pLKO.1)	clonetechGfp_58 7s1c1	5'-CCGG TGC CCG ACA ACC ACT ACC TGA CTCGAG TCA GGT AGT GGT TGT CGG GCA TTTTT-3'
TAZ shRNA1 (pLKO.1)	NM_000116	5'-CCGG TCC TAA CAG TCC GCC CTA CTT CTCGAG AAG TAG GGC GGA CTG TTA GGA TTTTTG-3'
TAZ shRNA2 (pLKO.1)	NM_000116	5'-CCGG TGC TTC CTC AGT TAC ACA AAG CTCGAG CTT TGT GTA ACT GAG GAA GCA TTTTTG-3'
Control shRNA (pRS19)	(Chan et al., 2015)	5'- ACCG GCA CTA CCA GAG CTA ACT CAG ATA GTA CT TCAAGAG AGTA CTA TCT GAG TTA GCT CTG GTA GTGC TTTT-3'
TAZ shRNA2 (pRS19)	NM_000116	5'-ACCG TGC TTC CTC AGT TAC ACA AAG TCAAGAG CTT TGT GTA ACT GAG GAA GCA TTTT -3'

Table S6. sgRNA or shRNA Sequences, Related to STAR Methods.

Lipids	Polarity	Molecular Ion	Mode	m/z ion	NCE	Approximate RT (min)
52:2 MLCL	-	[M-H]-	Top-5 DDA	1165.7666	17.5	11.55 - 11.88
52:3 MLCL	-	[M-H]-	Top-5 DDA	1163.7509	17.5	10.85 - 10.96
52:4 MLCL	-	[M-H]-	Top-5 DDA	1161.7353	17.5	8.79 - 9.53
54:2 MLCL	-	[M-H]-	Top-5 DDA	1193.7979	17.5	12.46 - 12.76
54:3 MLCL	-	[M-H]-	Top-5 DDA	1191.7822	17.5	11.45 - 11.90
54:4 MLCL	-	[M-H]-	Top-5 DDA	1189.7666	17.5	10.41 - 10.90
54:5 MLCL	-	[M-H]-	Top-5 DDA	1187.7509	17.5	9.26 - 9.71
54:6 MLCL	-	[M-H]-	Top-5 DDA	1185.7353	17.5	10.32 - 10.66
64:3 CL	-	[M-H]-	Top-5 DDA	1345.9188	17.5	14.51 - 14.74
66:2 CL	-	[M-H]-	Top-5 DDA	1375.9659	17.5	16.29 - 16.45
66:3 CL	-	[M-H]-	Top-5 DDA	1373.9502	17.5	15.41 - 15.70
66:4 CL	-	[M-H]-	Top-5 DDA	1371.9345	17.5	14.57 - 14.85
68:3 CL	-	[M-H]-	Top-5 DDA	1401.9816	17.5	16.23 - 16.55
68:4 CL	-	[M-H]-	Top-5 DDA	1399.9659	17.5	15.42 - 15.76
68:5 CL	-	[M-H]-	Top-5 DDA	1397.9493	17.5	14.71 - 14.98
70:4 CL	-	[M-H]-	Top-5 DDA	1427.9973	17.5	16.21 - 16.55
70:5 CL	-	[M-H]-	Top-5 DDA	1425.9817	17.5	15.54 - 15.85
70:6 CL	-	[M-H]-	Top-5 DDA	1423.9660	17.5	14.85 - 15.20
70:7 CL	-	[M-H]-	Top-5 DDA	1421.9503	17.5	15.43 - 15.73
72:5 CL	-	[M-H]-	Top-5 DDA	1454.0131	17.5	16.40 - 16.59
72:6 CL	-	[M-H]-	Top-5 DDA	1451.9974	17.5	15.69 - 15.97
72:7 CL	-	[M-H]-	Top-5 DDA	1449.9817	17.5	16.24 - 16.54
72:8 CL	-	[M-H]-	Top-5 DDA	1447.9661	17.5	15.55 - 15.81
72:9 CL	-	[M-H]-	Top-5 DDA	1445.9504	17.5	14.87 - 15.07
74:6 CL	-	[M-H]-	Top-5 DDA	1480.0288	17.5	16.52 - 16.59
74:7 CL	-	[M-H]-	Top-5 DDA	1478.0131	17.5	15.91 - 16.08
74:8 CL	-	[M-H]-	Top-5 DDA	1475.9975	17.5	16.36 - 16.61
74:9 CL	-	[M-H]-	Top-5 DDA	1473.9818	17.5	15.72 - 15.94

Table S7. Detection of Lipids by MS/MS, Related to STAR Methods. Abbreviations: MLCL = mono-lyso cardiolipin, CL – cardiolipin, DDA = data-dependent acquisition, m/z = mass-to-charge ratio, NCE = normalized collision energy, RT = retention time